Celebrating 80 Years of Inspiration for Life.
ABOUT THE MEETING
The Scientific Sessions offers researchers and health care professionals the unique opportunity to share ideas and learn about the significant advances and breakthroughs in diabetes.

Participants will receive exclusive access to more than 200 sessions and 2,000 original research presentations, take part in provocative and engaging exchanges with leading diabetes experts, expand their professional networks, and so much more.

The program is categorized into 8 distinct theme areas, allowing participants to focus on their specialty or expand their knowledge in other areas.

Theme Areas:
- Acute and Chronic Complications
- Behavioral Medicine, Clinical Nutrition, Education, and Exercise
- Clinical Diabetes/Therapeutics
- Epidemiology/Genetics
- Immunology/Transplantation
- Insulin Action/Molecular Metabolism
- Integrated Physiology/Obesity
- Islet Biology/Insulin Secretion

Don’t miss this opportunity to join your colleagues at the world’s largest, most prestigious meeting on diabetes — the American Diabetes Association’s 80th Scientific Sessions (#ADA2020)!

LOCATION AND DATES
The meeting will take place at the McCormick Place Convention Center (West and South Buildings) 2301 South Indiana Avenue, Chicago, IL 60616.

The program will begin on Friday, June 12 at 11:30 a.m., and conclude on Tuesday, June 16 at 12:15 p.m.

LEARNING OBJECTIVES
The Scientific Sessions offers comprehensive educational programming covering the latest in the field of diabetes. The program is designed for physicians, scientists, researchers, nurses, dietitians, pharmacists, psychologists, and other health care professionals.

At the conclusion of this activity attendees will be able to:
- Identify the 2020 ADA Standards of Care for classifying, diagnosing, preventing, and treating prediabetes and diabetes
- Assess non-pharmacologic treatment options for individualizing treatment protocols for the management of hyperglycemia and hypoglycemia
- Apply clinical decision-making tools to the assessment and treatment of the complications related to diabetes
- Develop a more aggressive, effective, physiological, psychological, and behavioral treatment plan for patients with diabetes
- Cite the research into current, emerging, and novel therapies for type 1 and type 2 diabetes
- Discuss proven education strategies for increasing the impact of diabetes education with individual patients
- Interpret the latest findings in the areas of epidemiology, genetics, immunology, transplantation, and islet biology as they relate to diabetes

MEETING HIGHLIGHTS
Special Addresses and Award Lectures
- President, Health Care & Education Address
  Mary de Groot, PhD
- President, Medicine & Science Address
  Robert H. Eckel, MD
- Banting Medal for Scientific Achievement
  Ele Ferrannini, MD
- Outstanding Scientific Achievement Award Lecture
  Jiandie Lin, PhD
- Outstanding Educator in Diabetes Award Lecture
  William Polonsky, PhD, CDE
- Kelly West Award for Outstanding Achievement in Epidemiology Lecture
  Elizabeth Selvin, PhD, MPH
- Richard R. Rubin Award Lecture
  Randi Streisand, PhD, CDE
- Roger Pecoraro Award Lecture
  Lee J. Sanders, DPM
- Norbert Freinkel Award Lecture
  David Simmons, MD, MA, FRCP, FACP, FRGS
- Edwin Bierman Award Lecture
  Rama Natarajan, PhD, FAHA, FASN

IMPORTANT DATES TO REMEMBER

<table>
<thead>
<tr>
<th>Event</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Last day to register at the Advance rate</td>
<td>April 30</td>
</tr>
<tr>
<td>Last day to cancel meeting registration and receive a partial refund (50% of registration fee)</td>
<td>April 30</td>
</tr>
<tr>
<td>Last day to reserve hotel rooms</td>
<td>May 15</td>
</tr>
<tr>
<td>Cancel hotel reservations to avoid penalty</td>
<td>72 hours prior to arrival</td>
</tr>
</tbody>
</table>
Highly Anticipated Study Announcements
In addition to more than 200 sessions, we are excited to announce that the first reported findings or new data to the following studies will be presented during the meeting.

Make your travel reservations accordingly so that you can attend all of these great sessions in person!

- Results of the eValuation of ERTugliflozin Efficacy and Safety CardioVascular Outcomes Trial (VERTIS-CV)
- New Data on Clinical Outcomes from the Diabetes Prevention Program Outcomes Study (DPPOS)
- DAPA-HF Update—Have We Lost SGLT2 Inhibitors to Cardiologists?!
- Special Concerns of Pregnancy with Preexisting Type 2 Diabetes, Including Metformin in Women with Type 2 Diabetes in Pregnancy (MiTy) Trial Results
- Update from the TEDDY Study
- Twenty Years of Pediatric Diabetes Surveillance—What Do We Know and Why It Matters—The SEARCH for Diabetes in Youth Study
- The Next Generation of Automated Insulin Delivery Systems for Persons with Type 1 Diabetes—Four New Clinical Trials
- Verifying a Strategic, Initial Combination Approach to Diabetics Management
- New Insights from the Restoring Insulin Secretion (RISE) Study—Differences Between Adults and Youth with Prediabetes and Type 2 Diabetes

Mini-Symposia
Mini-Symposia are 1-hour sessions that normally include 1-2 speakers. Speakers present on a topic for a maximum of 20 minutes with the remainder of the time devoted to questions and discussion with the audience.

Professional Interest Groups
Professional Interest Group Discussions are held Saturday, Sunday, and Monday during the lunchtime hour. Expect lively conversations, dialogue, and debate with professionals in your specialty such as islet biology, quality improvement, and technology. Learn more and join two groups today at professional.diabetes.org/interestgroups.

Oral Presentations
Abstracts selected for oral presentation are considered to be the best of the thousands of abstracts submitted to the Scientific Sessions. Choose from over 370 original presentations highlighting the most innovative research not found at any other meeting.

Poster Presentations
Explore more than 2,000 posters displaying the latest investigative methods in the Poster Hall on Saturday, Sunday, and Monday. Poster presenters will be at their poster boards for 1-hour on an assigned day to discuss their research with attendees.

ePosters
Each poster will have a corresponding barcode on its board. Scan the barcode with your smartphone, tablet, or handheld device to access an electronic version of the poster, corresponding abstract, and audio commentary (if provided). Computer kiosks will also be located within the Poster Hall for ePoster viewing.

Moderated Poster Discussions
Moderators will lead attendees on tours of up to 6 posters sharing their perspectives and highlighting novel or recent advancements in question and answer discussions with presenters. Discussions will take place on Saturday, Sunday, and Monday in the Poster Hall.

ePoster Theaters
Select posters will be presented electronically using ePosters. As with the Moderated Poster Discussions, up to 6 ePosters will be included in each theater. Sessions will take place on Saturday, Sunday, and Monday at ePoster Theaters A and B in the Exhibit Hall.

Earn up to 35 Continuing Education Credits
Continuing Education Credit is available for physicians, family physicians, international physicians, physician assistants, nurses, pharmacists, dietitians, psychologists, social workers, and certified diabetes educators.

ADA Events Mobile App
Access the meeting on-the-go. Download the Scientific Sessions Mobile App to access information on your smartphone, tablet, or handheld device.

Visit scientificsessions.diabetes.org in mid-May for more details.

EXHIBIT HALL
Over 130 exhibitors will be on hand to showcase their products and services to enhance your understanding of the latest groundbreaking technology and resources available today. The Exhibit Hall will be open on Saturday, Sunday, and Monday.
PRODUCT THEATERS
Industry experts will provide insight into diabetes services and products and demonstrate innovative equipment and technologies. Product Theaters will be scheduled during morning, lunch, and afternoon breaks in the Exhibit Hall on Saturday, Sunday, and Monday.

CORPORATE SYMPOSIA
Corporate Symposia are satellite programs that are planned and conducted by the corporate community in conjunction with the Scientific Sessions. These programs provide attendees with additional education and information opportunities.

Pre-registered attendees will receive an email on or about April 1, which will include instructions on registering for the Corporate Symposia. Attendees who register after April 1 will be able to select the Corporate Symposia when registering. All programs will take place at the Hyatt Regency McCormick Place and the Marriott Marquis Chicago.

Visit scientificsessions.diabetes.org in early-April for the most up-to-date schedule.

WOMEN’S INTERPROFESSIONAL NETWORK
The Women’s Interprofessional Network of the ADA (WIN ADA), is the world’s leading network of women clinicians, scientists, and educators within the diabetes field. WIN ADA will host multiple events at the Scientific Sessions, including an interactive Mini-Symposium and an evening networking reception.

Learn more and become a WIN ADA member today at professional.diabetes.org/winada.

DIABETES IS PRIMARY
This interactive program, developed specifically for the primary care community, and held in conjunction with the Scientific Sessions will offer information needed to improve patient outcomes and enhance patient engagement. The program will be held on Friday, June 12.

Scientific Sessions attendees can sign up for Diabetes Is Primary when registering for the Scientific Sessions. Chicago-based clinicians not attending the Scientific Sessions can register at professional.diabetes.org/primary. (Registration will be $150 beginning May 1). Registration includes program admission, continuing education credits, course materials, and lunch.

Note: Diabetes Is Primary overlaps with other sessions held on Friday starting at 11:30 a.m.

SPECIAL EVENTS
ADA Networking Reception
Join us Friday evening at the McCormick Place Convention Center (West Building) to meet and network with your colleagues from across the country or around the world. This is a great opportunity to renew connections with friends and colleagues or make new ones. Hors d’oeuvres and refreshments will be provided.

5K@ADA Fun Run/Walk
The 5K@ADA Fun Run/Walk, supported by Novo Nordisk, will be held on Sunday morning at 6:30 a.m. Race in style by sporting a 5K@ADA running shirt available for $20 when you register for the meeting. A limited number of shirts will be available for purchase onsite for $25. Sign up for the Fun Run/Walk by visiting www.adas5k.com. The event is free to all registered attendees.

PHOTOGRAPHY/SOCIAL MEDIA
Photography
Allowing photographs of presentation slides at the Scientific Sessions will be at the discretion of the presenter/study author. Each presenter/study author will announce, verbally and visually on a slide at the beginning of their presentation, whether or not they approve of photos being taken of their slides. If allowed, attendees may take photographs during presentations provided that the photographs are for personal, noncommercial use and are not for publication or rebroadcast without the express written permission of the author. Attendees are prohibited from using flash photography or otherwise distracting the presenters or members of the audience. Photography is not permitted in the Exhibit Hall or Poster Hall.

Social Media
The ADA encourages the use of social media, when following the above photo policy and within embargo restrictions, to update followers on the latest news coming from the Scientific Sessions. To engage on social media be sure to use the official meeting hashtag, #ADA2020, in all of your posts. You can also follow these channels for meeting updates:

- Twitter: @ADA_DiabetesPro and @AmDiabetesAssn
- Facebook: @DiabetesPro and @AmericanDiabetesAssociation
- Instagram: @AmDiabetesAssn
- LinkedIn: American-Diabetes-Association
REGISTRATION CATEGORIES

**Member**
Medicine and Science or Health Care and Education Professional Members.

Have your Professional Member ID number available to register for the meeting as a member. Professional Members who purchase a full meeting registration will receive online access to the Scientific Sessions webcasts free of charge!

**Non-Member**
For those who are not Medicine and Science or Health Care and Education Professional Members.

Become a member when you register for the Scientific Sessions and save up to $320 on your registration.

**Student/Resident/Fellow**
Available to those currently enrolled in one of these programs. Proof of status in a program must be submitted in order to register.

**One-Day**
Provides admittance to all sessions, including the Exhibit and Poster Halls (if open), for the selected day. You are allowed to register for only 1 One-Day Registration.

*Note: Children under the age of 18, even if paid registrants, will not be permitted access to session rooms, the Exhibit Hall, or the Poster Hall. Exceptions will be made for nursing mothers, but for safety reasons, strollers cannot be allowed.*

REGISTRATION RATES

<table>
<thead>
<tr>
<th>CATEGORY</th>
<th><strong>ADVANCE 2/28/20 - 4/30/20</strong></th>
<th><strong>FINAL 5/1/20 - 6/16/20</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Member*</td>
<td>$575</td>
<td>$625</td>
</tr>
<tr>
<td>Non-Member</td>
<td>$895</td>
<td>$945</td>
</tr>
<tr>
<td>Student/Resident/Fellow</td>
<td>$300</td>
<td>$320</td>
</tr>
<tr>
<td>One-Day Registration — Member*</td>
<td>$310</td>
<td>$320</td>
</tr>
<tr>
<td>One-Day Registration — Non-Member</td>
<td>$400</td>
<td>$410</td>
</tr>
</tbody>
</table>

*To qualify for the Member rate your Medicine and Science or Health Care and Education Membership must be active through June 30, 2020 at the time of registration.

**Register Online**
Go to scientificsessions.diabetes.org and click on the “Registration Information” tab. Online registration is fast, easy, and secure. You will receive your confirmation letter and periodic updates via email. If you are unable to register online, a downloadable registration form is available on the Scientific Sessions website. Attendees should bring their confirmation letter with them onsite to receive their meeting materials. The QR code included on your confirmation letter will greatly speed you through registration. A picture ID will be required to pick up your registration materials.

**Questions?**
Contact the ADA Registration and Hotel Support Center Monday through Friday, 9:00 a.m. to 9:00 p.m. (Eastern Time) at 866-290-9910 (Toll Free U.S. & Canada) or +415-268-2086 (International). Visit the ADA Support Center at ada.cmrushelp.com/s/contactsupport.

**Media Registration**
The ADA provides complimentary access to the Scientific Sessions to credentialed members of the media, including print, broadcast, and online media for the express purpose of gathering news and information to produce press coverage of the 80th Scientific Sessions.

Media representatives welcome to attend include reporters, writers, photographers, and videographers. News organizations seeking media credentials must be represented by editorial staff, and media registration is limited to two individuals per outlet/news organization.

For further information regarding registration eligibility and submission requirements for your news organization, contact scisessionspress@diabetes.org with any questions.

**HOTEL INFORMATION**
Go to scientificsessions.diabetes.org and click on the “Hotel Information” tab. Reserving your room online allows you to see hotel availability in real-time and allows us to send confirmation letters instantly. It also gives us a fast and easy way to contact you via email with any changes or updates.

**Hotel Reservations**
Support the ADA by booking your hotel room within the Scientific Sessions housing block through our official housing company, CMR. Hotel reservations can be made until May 15 based on availability. A listing of official ADA hotels, with rates and a locator map, is available at scientificsessions.diabetes.org.

Reservations are available on a first-come, first-served basis. Reserve your room early for the best selection. All hotels require a credit card guarantee. If you are unable to reserve online, a downloadable housing form is available on the Scientific Sessions website.
International Group Organizers
If you are organizing an international group (five or more rooms) to attend the Scientific Sessions, you may reserve your hotel rooms through our official housing company's International Group Division, CMR's Global Group Services website at ada-cmrglobalgroupservices.com, or contact them via email at ada@cmr-globalgroupservices.com for an all-inclusive group housing package. For any questions regarding group registration, visit the ADA Support Center at ada.cmrushelp.com/s/contactsupport.

Warning/Be Aware!
There are companies operating on the internet that are claiming to offer registration and housing services for the Scientific Sessions. These companies are not affiliated with ADA and do not offer any services on its behalf. You may receive emails or phone calls from these companies urging you to book hotel rooms or register. Registration and housing should only be accessed from the ADA website, scientificsessions.diabetes.org, and reserved through ADA's official registration and housing provider, Convention Management Resources, (CMR). If you do not see this logo on the website, then they are not our official provider.

Hotel Cancellations and Changes
All requests for cancellations or changes can be made by going online or by contacting ADA's official housing company. Changes received after May 15 will be subject to hotel availability. Reservations must be cancelled at least 72 hours prior to arrival to avoid penalty charges.

ADA Shuttle Bus Transportation
Attendees who reserve their room within the Scientific Sessions housing block will receive a shuttle pass, enabling them to ride the ADA shuttle system at no additional cost. Attendees who reserve their rooms through other means will not receive a shuttle pass. Shuttle passes will be available for purchase in advance through the registration site and onsite at the meeting at a cost of $75 per person. The pass is valid throughout the duration of the meeting.

Questions?
Contact the ADA Registration and Hotel Support Center Monday through Friday, 9:00 a.m. to 9:00 p.m. (Eastern Time) at 866-290-9910 (Toll Free U.S. & Canada) or +415-268-2086 (International). Visit the ADA Support Center at ada.cmrushelp.com/s/contactsupport.

TRAVEL INFORMATION
Chicago’s prime location and two international airports give it unmatched accessibility. You can get to Chicago from nearly anywhere in the world at any time of day.

Airports:
Chicago O’Hare International Airport (ORD): Chicago O’Hare International Airport is located 16 miles west of downtown and is approximately a 40-60 minute drive (depending on traffic) to downtown.

Chicago Midway International Airport (MDW): Chicago Midway International Airport is located 11 miles south of downtown and is approximately a 25-35 minute drive (depending on traffic) to downtown.

Taxis:
Taxis from Chicago O’Hare International Airport to downtown are approximately $40-$50 one way.

Taxis from Chicago Midway International Airport to downtown are approximately $25-$35 one way.

Ride-Sharing Apps:
Uber and Lyft are available from both airports.

Shuttles:
GO Airport Express provides shared ride services to all downtown hotels.

Public Transportation (Chicago Transit Authority (CTA) ‘L’ Train):
The CTA Blue Line ‘L’ Train, which runs 24/7, connects directly to O’Hare International Airport. The O’Hare station is situated in the lower level concourse, which connects directly to Terminals 1, 2, and 3, and can be conveniently accessed from Terminal 5 via a free, airport shuttle train.

Visa Requirements
Attendees from outside the U.S. may need to apply for a visa at the American Embassy, consulate, or other visa issuing office in their country of origin. Please begin your visa application process as soon as possible, as it can take several months to receive approval.

If a letter of invitation is needed for your visa application, go to scientificsessions.diabetes.org and click on the “Travel and Transportation Information” tab to download the letter.

SPOTLIGHT ON CHICAGO
We look forward to welcoming you to Chicago, a city with 26 miles of uninterrupted lakefront, 15 miles of sandy beaches, an 18-mile bike path, and hundreds of beautiful parks all nestled within a skyline of architectural wonders.

If it’s Chicago’s roots that pique your interest, you can explore unique neighborhoods representing over 200 nationalities. The city’s cultural diversity influences everything from its food and art to its architecture.

You’ll find world-class accommodations, world-renowned museums, vibrant nightlife and music for every style, theater that’s home to world-premiere shows, and a dining scene with so many accolades that it’s in a class of its own. It’s this truly unique mix of global attractions and local charm that makes Chicago second to none.
Note: Upon submission of the online evaluation, the MOC points will be immediately transferred to the ABIM. As stated above and per the ABIM rules, the ADA does not have access nor the ability to upload points requested after the evaluation closes.

Physicians from Europe
UEMS/ACCME CME credit recognition: The American Medical Association (AMA) has an agreement of mutual recognition of CME credit with the UEMS. Under the terms of this agreement, the European Accreditation Council for Continuing Medical Education (EACCME), the accrediting arm of the UEMS, will convert CME credit for live activities certified by the AMA.

Family Physicians
Application for CME credit has been filed with the American Academy of Family Physicians. Determination of credit is pending.

Physician Assistants
The American Diabetes Association has been authorized by the American Academy of Physicians Assistants (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 35 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

Dietitians
The American Diabetes Association is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR). Registered dietitians (RDs) and dietetic technicians, registered (DTRs) will receive 35 continuing professional education units (CPEUs) for completion of this program/material. Activity Number: 152442.

Psychologists
Continuing Education (CE) credits for psychologists are provided through the co-sponsorship of the American Psychological Association (APA) Office of Continuing Education in Psychology (CEP). The APA CEP Office maintains responsibility for the content of the programs.

Social Workers
As a Jointly Accredited Organization, the American Diabetes Association is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. State and provincial regulatory boards have the final authority to determine whether an individual course may be accepted for continuing education credit. The American Diabetes Association maintains responsibility for this course. Social workers completing this course receive 35 continuing education credits.

Certified Diabetes Educators
To satisfy the requirement for renewal of certification by continuing education for the National Certification Board for Diabetes Educators (NCBDE), continuing education activities must be diabetes related and approved by a provider on the NCBDE List of Approved Providers (www.ncbde.org). NCBDE does not approve continuing education. The American Diabetes Association is on the NCBDE List of Approved Providers.

To Obtain Continuing Education Credit
Certificates of Completion/Attendance are provided to registered attendees based upon completion of the online evaluation. The link to the online evaluation will be emailed to participants on June 12, 2020. The continuing education evaluation system will be available through July 10, 2020.
<table>
<thead>
<tr>
<th>Time</th>
<th>Behavioral Medicine, Clinical Nutrition, Education, and Exercise</th>
<th>Clinical Diabetes/Therapeutics</th>
<th>Epidemiology/Genetics</th>
<th>Immunology/Transplantation</th>
<th>Insulin Action/Molecular Metabolism</th>
<th>Integrated Physiology/Obesity</th>
<th>Islet Biology/Insulin Secretion</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:30 a.m.-12:30 p.m.</td>
<td>Mini-Symposium Debate — Technology Alone Can Solve the Problem of Hypoglycemia in Diabetes</td>
<td>Mini-Symposium Improving Type 1 Diabetes Management in Young Adults — Time to (Re)Strategize?</td>
<td>Mini-Symposium The Impact of TODAY and RISE on Tomorrow — Updates in Pediatric Type 2 Diabetes Management</td>
<td>Mini-Symposium Diabetes and Genetic Predictors in Ethnically Diverse Populations</td>
<td>Mini-Symposium The Randle Debate — The Effects of Dietary Carbohydrate, Fat, and Calorie Intake on Metabolic Disease</td>
<td>Mini-Symposium Debate — Metabolic Changes Related to Alteration in Circadian Rhythm</td>
<td>Mini-Symposium Debate — Prenatal or Postnatal Environment in the Transmission of Obesity — Focus on the Womb or the Home?</td>
</tr>
<tr>
<td>12:45 p.m.-1:45 p.m.</td>
<td>Mini-Symposium Male Sexual Dysfunction in Diabetes</td>
<td>Mini-Symposium The Weight-Neutral Approach in Diabetes Management</td>
<td>Mini-Symposium Strategies and Tools to Improve the Transition from Pediatric to Adult Diabetes Care</td>
<td>Mini-Symposium Debate — Can We Rely on Nutrition Science for Diabetes and Cardiovascular Disease?</td>
<td>Mini-Symposium Combination Immunotherapy to Preserve Beta-Cell Function in Type 1 Diabetes</td>
<td>Mini-Symposium The Banting Exchange — Diabetes Discovery — How the Past Informs the Future</td>
<td>Mini-Symposium Are There Different Beta-Cell Subpopulations?</td>
</tr>
<tr>
<td>Time</td>
<td>Event</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>--------------</td>
<td>----------------------------------------------------------------------</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2:00 p.m.-</td>
<td>Symposium Doing Better for Diabetes and Chronic Kidney Disease (CKD)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4:00 p.m.</td>
<td>Symposium Using Technologies to Track Physical Activity and Improve Health</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Symposium Ethnic and Racial Disparities in Maternal, Perinatal, and Neonatal Mortality</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Symposium Update on Heart Failure for the Diabetologist</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Symposium Transitions in Diabetes</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Symposium Which Diet Is Best for Treatment of Diabetes and Obesity?</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Symposium The Next Generation of Automated Insulin Delivery Systems for Persons with Type 1 Diabetes — Four New Clinical Trials</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4:15 p.m.-</td>
<td>Symposium Diabetic Foot Management — Care Strategies for the Primary Care and Medical Teams</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6:15 p.m.</td>
<td>Symposium Taking the Technology Plunge — Integrating Digital Technology into Practice</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Symposium Expanding the Use of Continuous Glucose Monitoring in Pediatric Settings</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Symposium Tailoring Treatment Options Based on Diabetes Comorbidities</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Oral Presentations</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Oral Presentations</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Oral Presentations</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Oral Presentations</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Oral Presentations</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6:30 p.m.-</td>
<td>ADA Networking Reception/WIN ADA Networking Reception</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8:30 p.m.</td>
<td>ADA Networking Reception/WIN ADA Networking Reception</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
# DAY-AT-A-GLANCE SCHEDULE
## SATURDAY, JUNE 13, 2020

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00 a.m.-10:00 a.m.</td>
<td><strong>Acute and Chronic Complications</strong>&lt;br&gt;Symposium Reduction of Hypoglycemia by New Therapies in Clinical Trials — Overestimated, Underestimated, or Both?&lt;br&gt;<strong>Behavioral Medicine, Clinical Nutrition, Education, and Exercise</strong>&lt;br&gt;Symposium ADA Education Recognition Program Symposium — Clinical Considerations for Safe, Cultural, Spiritual, and Therapeutic Fasting among People with Diabetes&lt;br&gt;<strong>Clinical Diabetes/Therapeutics</strong>&lt;br&gt;Symposium Can Taxes Alter Dietary Behaviors and Outcomes?&lt;br&gt;Symposium ADA Diabetes Care Symposium — Long-Term Perspectives on Study and Care of Diabetes&lt;br&gt;<strong>Epidemiology/Genetics</strong>&lt;br&gt;Symposium The “Legacy Effect” in Diabetes — Are There Long-Term Benefits of Short-Term Tight Glycemic Management?&lt;br&gt;<strong>Immunology/Transplantation</strong>&lt;br&gt;Symposium Engaging the Immune System to Protect Beta Cells&lt;br&gt;<strong>Insulin Action/Molecular Metabolism</strong>&lt;br&gt;Symposium Metabolic Tracing in Nutrition, Diabetes, and Cancer&lt;br&gt;<strong>Integrated Physiology/Obesity</strong>&lt;br&gt;Symposium The Impact of Environmental Temperature on Metabolic Regulation&lt;br&gt;<strong>Oral Presentations</strong>&lt;br&gt;Oral Presentations</td>
</tr>
<tr>
<td>10:15 a.m.-11:30 a.m.</td>
<td>President, Health Care &amp; Education Address and Outstanding Educator in Diabetes Award Lecture</td>
</tr>
<tr>
<td>11:30 a.m.-12:30 p.m.</td>
<td><strong>Professional Interest Group Discussion on Foot Care</strong> — Motivational Interviewing to Help Patients Accomplish Self-Care of the Neuropathic Foot&lt;br&gt;<strong>Professional Interest Group Discussion on Exercise Physiology</strong> — The Molecular Transducers of Physical Activity (MoTPAC)&lt;br&gt;<strong>Professional Interest Group Discussion on Nutritional Science and Metabolism</strong> — Emerging Methodologies for Personalized Nutrition — Potential Effects on Glycemic and Other Diabetes-Related Outcomes?&lt;br&gt;<strong>Professional Interest Group Discussion on Clinical Centers and Programs</strong> — Frequently Encountered Glycemic Management Issues without Clear Guidelines&lt;br&gt;<strong>Professional Interest Group Discussion on Islet Biology, Development, and Function</strong> — Debate — Chewing the Fat on the Role of Glucolipotoxicity in Type 2 Diabetes</td>
</tr>
<tr>
<td>11:30 a.m.-12:30 p.m.</td>
<td>General Poster Session</td>
</tr>
<tr>
<td>11:30 a.m.-1:30 p.m.</td>
<td>Moderated Poster Discussions/ePoster Theater Sessions</td>
</tr>
<tr>
<td>Time</td>
<td>Acute and Chronic Complications</td>
</tr>
<tr>
<td>--------------</td>
<td>-------------------------------------------------</td>
</tr>
<tr>
<td>1:45 p.m.-3:45 p.m.</td>
<td>Symposium Clinical Management of Diabetic Neuropathies in 2020</td>
</tr>
<tr>
<td>4:00 p.m.-6:00 p.m.</td>
<td>Symposium DAPA-HF Update — Have We Lost SGLT2 Inhibitors to Cardiologists?!</td>
</tr>
<tr>
<td></td>
<td>Symposium Dilemmas in Diabetic Foot Infection Management</td>
</tr>
<tr>
<td>Time</td>
<td>Section</td>
</tr>
<tr>
<td>--------------</td>
<td>-------------------------------------------------------------------------</td>
</tr>
<tr>
<td>8:00 a.m.-</td>
<td>Symposium Cardiorenal–Metabolic Axis in Diabetes Oral Presentations</td>
</tr>
<tr>
<td>10:00 a.m.</td>
<td>Symposium Lifestyle Interventions for Type 2 Diabetes Remission Oral</td>
</tr>
<tr>
<td></td>
<td>Presentations</td>
</tr>
<tr>
<td></td>
<td>Symposium Adjunctive Glucose-Lowering Therapies for Adults with Type 1 Diabetes — Evidence</td>
</tr>
<tr>
<td></td>
<td>Oral Presentations</td>
</tr>
<tr>
<td></td>
<td>Symposium ADA Diabetes Symposium — Unraveling the Heterogeneity in</td>
</tr>
<tr>
<td></td>
<td>Type 2 Diabetes</td>
</tr>
<tr>
<td>10:15 a.m.-</td>
<td>President, Medicine &amp; Science Address and Banting Medal for Scientific</td>
</tr>
<tr>
<td>11:45 a.m.</td>
<td>Achievement</td>
</tr>
<tr>
<td>12:00 p.m.-</td>
<td>Professional Interest Group Discussion on Diabetes and Cardiovascular</td>
</tr>
<tr>
<td>1:00 p.m.</td>
<td>Disease — Hot Topics in Diabetes Cardiovascular Disease Management</td>
</tr>
<tr>
<td></td>
<td>Professional Interest Group Discussion on Eye Health — Common</td>
</tr>
<tr>
<td></td>
<td>Questions Encountered by Diabetes Care Providers Related to Eye Issues</td>
</tr>
<tr>
<td></td>
<td>Experienced by People with Diabetes</td>
</tr>
<tr>
<td></td>
<td>Professional Interest Group Discussion on Behavioral Medicine and</td>
</tr>
<tr>
<td></td>
<td>Psychology — The Value Proposition for Behavioral Health — Examples of</td>
</tr>
<tr>
<td></td>
<td>Effectively Making the Case</td>
</tr>
<tr>
<td></td>
<td>Professional Interest Group Discussion on Diabetes Self-Management</td>
</tr>
<tr>
<td></td>
<td>Education and Support (DSMES) — Focus on 2020 DSMES Consensus Report</td>
</tr>
<tr>
<td></td>
<td>Mini-Symposium Women’s Intergroup Network of the ADA (WIN ADA) —</td>
</tr>
<tr>
<td></td>
<td>Personal Wellness</td>
</tr>
<tr>
<td>12:00 p.m.-</td>
<td>General Poster Session/Moderated Poster Discussions/ePoster Theater</td>
</tr>
<tr>
<td>1:00 p.m.</td>
<td>Sessions</td>
</tr>
<tr>
<td>2:00 p.m.</td>
<td>Session Break (Take this opportunity to visit the Exhibit and Poster Halls)</td>
</tr>
<tr>
<td>Time</td>
<td>Acute and Chronic Complications</td>
</tr>
<tr>
<td>--------------</td>
<td>-------------------------------------------------</td>
</tr>
<tr>
<td>2:15 p.m.-4:15 p.m.</td>
<td>Symposium Update on Lipid-Lowering Drugs</td>
</tr>
<tr>
<td></td>
<td>Symposium New Perspectives on Diabetic Retinopathy Diagnosis and Treatment</td>
</tr>
</tbody>
</table>

Registration Hours: 7:30 a.m.-5:00 p.m.
ADA Bookstore Hours: 7:30 a.m.-6:45 p.m.
Exhibit Hall Hours: 10:00 a.m.-4:00 p.m.
Poster Hall Hours: 7:30 a.m.-6:30 p.m.
**DAY-AT-A-GLANCE SCHEDULE**
**MONDAY, JUNE 15, 2020**

<table>
<thead>
<tr>
<th>Time</th>
<th>Section</th>
</tr>
</thead>
</table>
| 8:00 a.m.-10:00 a.m. | Oral Presentations  
Symposium: Addressing Care Gaps — New Frontiers for Diabetes Nutrition Providers and Services  
Symposium: Utilizing Diabetes Technology in the Real World — Tools of the Trade  
Symposium: How Do GLP-1 Receptor Agonists Provide Cardioprotection?  
Symposium: Joint ADA/AACC Symposium — Point-of-Care HbA1c — Should We Use It to Diagnose Diabetes?  
Symposium: Update from the TEDDY Study  
Oral Presentations |
| 10:10 a.m.-11:45 a.m. | National Scientific & Health Care Achievement Awards Presentation and Outstanding Scientific Achievement Award Lecture |
| 12:00 p.m.-1:00 p.m. | Professional Interest Group Discussion on Diabetes Technology — Interpreting Time-in-Range in Different Populations and Situations  
Professional Interest Group Discussion on Health Care Delivery and Quality Improvement — Leveraging Population Health Methods to Improve Diabetes Care  
Professional Interest Group Discussion on Pregnancy and Reproductive Health — All Pregnant Women with Preexisting Diabetes Should Take Low-Dose Aspirin to Prevent Preeclampsia  
Professional Interest Group Discussion on Public Health and Epidemiology — Diabetes and Built Environment  
Professional Interest Group Discussion on Immunology, Immunogenetics, and Transplantation — Next Generation in Immunotherapy in Type 1 Diabetes |
| 12:00 p.m.-1:00 p.m. | General Poster Session/Moderated Poster Discussions/ePoster Theater Sessions |
| 1:00 p.m.-2:00 p.m. | Session Break (Take this opportunity to visit the Exhibit and Poster Halls) |
### DAY-AT-A-GLANCE SCHEDULE

**MONDAY, JUNE 15, 2020 (CONTINUED)**

<table>
<thead>
<tr>
<th>Time</th>
<th>Section</th>
</tr>
</thead>
<tbody>
<tr>
<td>2:15 p.m.-</td>
<td>Symposium: Hypoglycemia — All about the Brain</td>
</tr>
<tr>
<td>4:15 p.m.</td>
<td><strong>Oral Presentations</strong></td>
</tr>
<tr>
<td>4:30 p.m.-</td>
<td>Symposium: Novel Approaches for Cell and Tissue Interrogation — Using</td>
</tr>
<tr>
<td>6:30 p.m.</td>
<td>the Kidney as a Model</td>
</tr>
<tr>
<td></td>
<td><strong>Oral Presentations</strong></td>
</tr>
</tbody>
</table>

#### Behavioral Medicine, Clinical Nutrition, Education, and Exercise

<table>
<thead>
<tr>
<th>Time</th>
<th>Section</th>
</tr>
</thead>
<tbody>
<tr>
<td>2:15 p.m.-</td>
<td>Symposium: Disparities in Diabetes and Diabetes Care — What Can We Do</td>
</tr>
<tr>
<td>4:15 p.m.</td>
<td>about It?</td>
</tr>
<tr>
<td></td>
<td><strong>Symposium</strong></td>
</tr>
<tr>
<td></td>
<td>Physical Activity and Diabetes — When, How Much, Insulin Adjustments,</td>
</tr>
<tr>
<td></td>
<td>and More</td>
</tr>
</tbody>
</table>

#### Clinical Diabetes/Therapeutics

<table>
<thead>
<tr>
<th>Time</th>
<th>Section</th>
</tr>
</thead>
<tbody>
<tr>
<td>2:15 p.m.-</td>
<td>Symposium: Current Issues (2:15 p.m.-3:10 p.m.) — Debate — Primary</td>
</tr>
<tr>
<td>4:15 p.m.</td>
<td>Cardiovascular Prevention with SGLT2 Inhibitors or GLP-1 Receptor</td>
</tr>
<tr>
<td></td>
<td>Agonists — Are We Ready for Prime Time?</td>
</tr>
<tr>
<td></td>
<td><strong>Symposium</strong></td>
</tr>
<tr>
<td></td>
<td>Artificial Intelligence (AI), Machine Learning, and Diabetes</td>
</tr>
<tr>
<td></td>
<td><strong>Symposium</strong></td>
</tr>
<tr>
<td></td>
<td>Fetal Sex and Pregnancy Outcomes</td>
</tr>
<tr>
<td></td>
<td><strong>Symposium</strong></td>
</tr>
<tr>
<td></td>
<td>Chinese Diabetes Society Symposium — Novel Antidiabetic Approaches</td>
</tr>
<tr>
<td></td>
<td>and Potential Targets</td>
</tr>
<tr>
<td></td>
<td><strong>Symposium</strong></td>
</tr>
<tr>
<td></td>
<td>(3:15 p.m.-4:15 p.m.) — Weekly Basal Insulin — The Wave of the Future?</td>
</tr>
</tbody>
</table>

#### Immunology/Transplantation

<table>
<thead>
<tr>
<th>Time</th>
<th>Section</th>
</tr>
</thead>
<tbody>
<tr>
<td>2:15 p.m.-</td>
<td>Symposium: Twenty Years of Pediatric Diabetes Surveillance — What Do</td>
</tr>
<tr>
<td>4:15 p.m.</td>
<td>We Know and Why It Matters — The SEARCH for Diabetes in Youth Study</td>
</tr>
</tbody>
</table>

#### Epidemiology/Genetics

<table>
<thead>
<tr>
<th>Time</th>
<th>Section</th>
</tr>
</thead>
<tbody>
<tr>
<td>2:15 p.m.-</td>
<td>Symposium: The Human Pancreas in Type 1 Diabetes</td>
</tr>
</tbody>
</table>

#### Insulin Action/Molecular Metabolism

<table>
<thead>
<tr>
<th>Time</th>
<th>Section</th>
</tr>
</thead>
<tbody>
<tr>
<td>2:15 p.m.-</td>
<td>Symposium: Inter-organ Cross Talk in Physiology and Metabolic Disease</td>
</tr>
</tbody>
</table>

#### Integrated Physiology/Obesity

<table>
<thead>
<tr>
<th>Time</th>
<th>Section</th>
</tr>
</thead>
<tbody>
<tr>
<td>2:15 p.m.-</td>
<td>Symposium: It's All in the Timing — Time and Age-Related Changes in Islet</td>
</tr>
<tr>
<td>4:15 p.m.</td>
<td>Function</td>
</tr>
</tbody>
</table>

#### Oral Presentations

<table>
<thead>
<tr>
<th>Time</th>
<th>Section</th>
</tr>
</thead>
<tbody>
<tr>
<td>2:15 p.m.-</td>
<td>Symposium: Novel Approaches for Cell and Tissue Interrogation — Using</td>
</tr>
<tr>
<td>4:15 p.m.</td>
<td>the Kidney as a Model</td>
</tr>
<tr>
<td></td>
<td><strong>Oral Presentations</strong></td>
</tr>
<tr>
<td></td>
<td>Symposium: The Year in Review — Highlights of the Past Year in Basic,</td>
</tr>
<tr>
<td></td>
<td>Translational, and Clinical Science</td>
</tr>
<tr>
<td></td>
<td><strong>Symposium</strong></td>
</tr>
<tr>
<td></td>
<td>Interpreting Cardiovascular Outcomes Trials — Implications for Practice</td>
</tr>
<tr>
<td></td>
<td><strong>Oral Presentations</strong></td>
</tr>
<tr>
<td>2:15 p.m.-</td>
<td>Symposium: Perspectives on the Future of Precision Diabetes Medicine</td>
</tr>
<tr>
<td>4:15 p.m.</td>
<td>— A Joint ADA/EASD Symposium</td>
</tr>
<tr>
<td></td>
<td><strong>Oral Presentations</strong></td>
</tr>
</tbody>
</table>

#### Islet Biology/Insulin Secretion

<table>
<thead>
<tr>
<th>Time</th>
<th>Section</th>
</tr>
</thead>
<tbody>
<tr>
<td>2:15 p.m.-</td>
<td>Symposium: Cognitive Function in Obesity and Appetite Regulation</td>
</tr>
<tr>
<td>4:15 p.m.</td>
<td><strong>Oral Presentations</strong></td>
</tr>
</tbody>
</table>

**Registration Hours:** 7:30 a.m.-4:00 p.m.  
**ADA Bookstore Hours:** 7:30 a.m.-6:45 p.m.  
**Exhibit Hall Hours:** 10:00 a.m.-2:00 p.m.  
**Poster Hall Hours:** 7:30 a.m.-2:00 p.m.
## DAY-AT-A-GLANCE SCHEDULE
### TUESDAY, JUNE 16, 2020

<table>
<thead>
<tr>
<th>Time</th>
<th>Acute and Chronic Complications</th>
<th>Behavioral Medicine, Clinical Nutrition, Education, and Exercise</th>
<th>Clinical Diabetes/Therapeutics</th>
<th>Epidemiology/Genetics</th>
<th>Immunology/Transplantation</th>
<th>Insulin Action/Molecular Metabolism</th>
<th>Integrated Physiology/Obesity</th>
<th>Islet Biology/Insulin Secretion</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00 a.m. - 10:00 a.m.</td>
<td>Current Issues (8:00 a.m.-8:55 a.m.) Debate — Microvascular and Macrovascular Complications of Diabetes Are Distinct Pathophysiologic Entities [Current Issues](9:00 a.m.-10:00 a.m.) Debate — Drawing the Line between Primary and Secondary Prevention — Necessary or Too Simplistic?</td>
<td>Symposium Diabetes Meets the Sandman — Sleep, Diabetes, and Glycemic Management</td>
<td>Symposium SGLT2 Inhibitors — How Do They Reduce Cardiovascular Disease?</td>
<td>Symposium New Data on Clinical Outcomes from the Diabetes Prevention Program Outcomes Study (DPPOS)</td>
<td>Symposium Immune Intervention During the Stages of Type 1 Diabetes Development — Type 1 Diabetes TrialNet</td>
<td>Symposium Economic Drivers of Obesity Treatment — From Individuals to Systems</td>
<td>Symposium What’s New with GLP-1?</td>
<td></td>
</tr>
<tr>
<td>10:15 a.m. - 12:15 p.m.</td>
<td>Symposium Results of the eValuation of ERTugliflozin Efficacy and Safety CardioVascular Outcomes Trial (VERTIS-CV)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
11:30 a.m.-12:30 p.m.

• Debate — Technology Alone Can Solve the Problem of Hypoglycemia in Diabetes
  For — Technology Alone Can Solve the Problem of Hypoglycemia
  Richard M. Bergenstal, MD
  Against — Technology Alone Can Solve the Problem of Hypoglycemia
  Emma G. Wilmot, MD
  Question and Discussion Period

• Is a Routine Lipid Panel Sufficient for Determining Cardiovascular Risk?
  When Should You Order Advanced Lipoprotein Testing?
  Ronald M. Krauss, MD
  When Should You Order Coronary Calcium Scans?
  Matthew Budoff, MD
  Question and Discussion Period

• Sex Differences in Renal and Cardiovascular Disease in Diabetes
  Pathophysiology of Sex Differences in Micro- and Macrovascular Complications in Diabetes Mellitus
  Christine Maric-Bilkan, PhD
  Is There a Role of Sex in the Progression of Renal and Cardiovascular Disease in Diabetes?
  Joel Neugarten, MD, JD
  Question and Discussion Period

• Improving Type 1 Diabetes Management in Young Adults — Time to (Re)Strategize?
  "Adulting" with Diabetes — Things to Teach the Hard to Reach
  Persis V. Commissariat, PhD
  The Simple Magic of Peer Connections in Type 1 Diabetes — Lessons from the College Diabetes Network
  Anna Floren Sabino, MSW, CDCES
  Using Lived Experiences as a Mechanism for Engagement in Diabetes Care
  Jennifer Saylor, PhD, APRN, ACNS-BC
  Question and Discussion Period

12:45 p.m.-1:45 p.m.

• Male Sexual Dysfunction in Diabetes
  Erectile Dysfunction in Diabetes — Epidemiology, Pathogenesis, and Psychological Aspects
  Aruna V. Sarma, PhD
  Medical Management of Erectile Dysfunction
  Deepak K. Jumani, MBBS, FCGP
  Question and Discussion Period

2018 Physical Activity Guidelines for Americans
What Are the 2018 Physical Activity Guidelines for People of All Ages?
Katrina L. Piercy, PhD, RD, ACSM-CEP
How Applicable Are the 2018 Physical Activity Guidelines to Youth and Adults with Diabetest?
Ronald J. Sigal, MD, MPH, FRCP
Question and Discussion Period

The Impact of TODAY and RISE on Tomorrow — Updates in Pediatric Type 2 Diabetes
Update — Medication Management Strategies for Youth-Onset Type 2 Diabetes
Jane L. Lynch, MD
Comparing Complication Rates in Pediatric Type 2 Diabetes, Adult Type 2 Diabetes, and Youth with Type 1 Diabetes
Barbara H. Braffett, PhD
Question and Discussion Period

Female Sexual Dysfunction in Diabetes — Therapeutic Interventions
Female Sexual Dysfunction — Pharmacological Interventions
Alice Y.Y. Cheng, MD, FRCPC
Female Sexual Dysfunction — Sex Counseling Therapy Evidence
Sharon J. Parish, MD
Question and Discussion Period

Diabetes and Genetic Predictors in Ethnically Diverse Populations
Genetic Factors Influencing Complex Metabolic Traits in Ethnically Diverse Africans
Sarah A. Tishkoff, PhD
Precision Diabetes Genetic Medicine in Asia — The Taichung Experience
Wayne H-H Sheu, MD, PhD
Question and Discussion Period

Bioengineered Cell Therapy for Diabetes
Generation and Analysis of Immune Cloaked Beta Cells from Human Stem Cells
Audrey Parent, PhD
Islet Microchip Technology
Maike Sander, MD
Islet Bioprinting
Francesca Spagnoli, MD, PhD
Question and Discussion Period

The Randle Debate — The Effects of Dietary Carbohydrate, Fat, and Calorie Intake on Metabolic Disease
Dietary Fat as a Cause of Metabolic Disease
Sarah Hallberg, DO, MS, ACSM-CEP, FOMA, FNLA
Dietary Carbohydrate as a Cause of Metabolic Disease
Barbara E. Corkey, PhD
Dietary Quality and Calories as a Cause of Metabolic Disease
Kevin D. Hall, PhD
Question and Discussion Period

Debate — Prenatal or Postnatal Environment in the Transmission of Obesity — Focus on the Womb or the Home?
Focus on the Womb
Ian Paul, MD, MSc
Focus on the Home
Paula C. Chandler-Laney, PhD
Question and Discussion Period

Debate — Technology Alone Can Solve the Problem of Hypoglycemia in Diabetes
For — Technology Alone Can Solve the Problem of Hypoglycemia
Richard M. Bergenstal, MD
Against — Technology Alone Can Solve the Problem of Hypoglycemia
Emma G. Wilmot, MD
Question and Discussion Period

Debate — Metabolic Changes Related to Alteration in Circadian Rhythm
Point — It’s All about Sleep
Josiane L. Broussard, PhD
Counterpoint — It’s All about Food
Andrew W. McHill, PhD
Rebuttal
Josiane L. Broussard, PhD
Rebuttal
Andrew W. McHill, PhD
Question and Discussion Period

Debate — Technology Alone Can Solve the Problem of Hypoglycemia in Diabetes
For — Technology Alone Can Solve the Problem of Hypoglycemia
Richard M. Bergenstal, MD
Against — Technology Alone Can Solve the Problem of Hypoglycemia
Emma G. Wilmot, MD
Question and Discussion Period

Speakers and presentation titles are subject to change.
• Diabetic Retinopathy Detection and Treatment in Resource-Constrained Areas
  Implementing a Diabetic Retinopathy Referral Network and Treatment in Peru
  Omar Salamanca, MD
  Implementing a Diabetic Retinopathy Research Network and Treatment in Latin America
  J. Fernando Arevalo, MD, PhD, FACS
  Question and Discussion Period

• The Future Is Now — Designing Smarter Trials for Cardiovascular Protection in Diabetes
  2008 FDA Guidelines on Antidiabetic Therapies Has Served Its Purpose — Time to Move On
  Milton Packer, MD
  2008 FDA Guidelines on Antidiabetic Therapies Is Still Relevant
  Steven Nissen, MD
  What Are the Gaps in the Evidence, and How to Target Them?
  Ann Marie Navar, MD, PhD
  Panel Discussion
  Bruce M. Psaty, MD, PhD
  Peter Stein, MD
  Lisa Yanoff, MD

• Functional Outcomes in Diabetic Foot following Amputation
  High- vs. Low-Level Amputations
  George T. Liu, DPM, FACFAS
  Advancements in Prosthetic Devices
  Phillip Stevens, MEd, CPO
  Question and Discussion Period

• The Weight-Neutral Approach in Diabetes Management
  Definition and Benefits of a Weight-Neutral Approach
  Erin Phillips, MPH, RDN, CDE
  Implementing Weight-Neutral Care in Diabetes Management
  Holly Paulsen, RD, CEDRD-S, LD
  Question and Discussion Period

• Creative Mealtime Boluses for Pumps and Multiple Daily Injections
  Creative Insulin Pump Bolusing — Practice Makes Perfect
  Margaret Pellizzari, MBA, MS, RN, CDCES, CDTc, FDcES
  Optimizing Mealtime Insulin Dosing for Patients on Multiple Daily Injections — High-Fat Meals and More
  Amy Hess Fischl, MS, RDN, LDN, BC-ADM, CDE
  Question and Discussion Period

• Strategies and Tools to Improve the Transition from Pediatric to Adult Diabetes Care
  A U.S. Perspective
  Robert S. Zimmerman, MD
  A Canadian Perspective
  Sonia Butalia, BSc, MD, FRcpc, MSc (epi)
  Question and Discussion Period

• Special Concerns of Pregnancy with Preexisting Type 2 Diabetes, Including Metformin in Women with Type 2 Diabetes in Pregnancy (MiTy) Trial Results
  Findings from the MiTy Trial
  Denice Feig, MD, MSc, FRcpc
  Special Considerations of Type 2 Diabetic Pregnancy
  Linda (Lynn) A. Barbour, MD, MSPH, FACP
  Question and Discussion Period

• Debate — Can We Rely on Nutrition Science for Diabetes and Cardiovascular Disease?
  No, and Why Not — A Critique of Diet-Centrism
  Edward Archer, PhD
  Yes, and Why So
  Walter C. Willett, MD
  Question and Discussion Period

• Combination Immunotherapy to Preserve Beta-Cell Function in Type 1 Diabetes
  Combination Immune Therapies in Type 1 Diabetes — What Have We Tried?
  Peter Gottlieb, MD
  Combination Immune Therapies in Type 1 Diabetes — Where Do We Go Next?
  Linda DiMeglio, MD, MPH
  Question and Discussion Period

• The Banting Exchange — Diabetes Discovery — How the Past Informs the Future
  Is Beta-Cell Failure Reversible?
  Domenico Accili, MD
  Can Lipids Improve Insulin Resistance and Beta-Cell Function?
  Barbara B. Kahn, MD
  Question and Discussion Period

• Are There Different Beta-Cell Subpopulations?
  Single-Cell Approaches Revealed Disease-Associated Beta-Cell Heterogeneity
  Yan Li, PhD
  The Challenges We Face to Detect Beta-Cell Subpopulations
  Mark Huising, PhD
  Question and Discussion Period

2:00 p.m. – 4:00 p.m.

• Doing Better for Diabetes and Chronic Kidney Disease (CKD)
  The Worldwide Impact of Diabetes and CKD
  Nilka Rios Burrows, MT, MPH
  Identification of Diabetes and CKD in Clinical Practice
  Susanne Nicholas, MD, MPH, PhD
  Recommendations for Glycemia Monitoring and Targets in CKD
  Peter Rossing, MD, DMSc
  Recommended Therapies for the Treatment of CKD in Diabetes
  Katherine R. Tuttle, MD, FACP, FASN, FNKF

• Using Technologies to Track Physical Activity and Improve Health
  Physical Activity Tracking — Technology under the Hood
  Kong Y. Chen, PhD, MSCI
  Learning from Smartphone Sensor Data — Activity, Location, and Sociability
  Ashutosh Sabharwal, PhD
  Being Physically Active with Artificial Pancreas Systems and Continuous Glucose Monitoring
  Dessi Zaharieva, PhD
  Activity and the Type 2 Diabetes Digital Ecosystem — Insights from Technology
  David Kerr, MD

• Ethnic and Racial Disparities in Maternal, Perinatal, and Neonatal Mortality
  Ethnic Disparities in Maternal Pregnancy Complications and Mortality
  Marissa H. Platner, MD
  Ethnic Disparities in Preterm Birth and Neonatal Survival
  Heather H. Burris, MD, MPH
  Prospective Longitudinal Study of the Pregnancy DNA Methylome — The U.S. Pregnancy, Race, Environment, Genes (PREG) Study
  Dana Lapato, PhD
Risk and Protective Factors among Racially/Ethnically Diverse Women with Gestational Diabetes
Susan D. Brown, PhD

Ethnic Differences in Neonatal Health in Premature Infants
Teresa Janevic, PhD, MPH

Question and Discussion Period

• Update on Heart Failure for the Diabetologist
Classification of Heart Failure (HFP EF, HFREF, etc.)
Kim A. Connelly, MBBS, PhD, FRACP
What Is the Current Standard of Care for Heart Failure with Nonantihyperglycemic Medications?
Clyde W. Yancy, MD, MSc, MACC, FAHA, MACP, FHFS...

• Transitions in Diabetes
Diabetes Transitions in the Hospital — Strategies to Consider when the Formulary Does Not Match Your Patient’s Home Insulin
Irl B. Hirsch, MD
Diabetes Management in a Long-Term Care Facility — Strategies for Providers
Ruth S. Weinstock, MD, PhD
Translating Across Time Zones — Diabetes Management Across the Country and Around the World
Subbulaxmi Trikudanathan, MD, MRCP, MMSc

• Which Diet Is Best for Treatment of Diabetes and Obesity?
Low-Calorie Diets
John Wilding, DM, FRCP
Low-Carbohydrate Diets and Nutritional Ketosis
Jessica Turton, APD, BAppSc (Ex&SpSc), MNutrDiet
Intermittent Fasting
Thomas Pieber, MD
Mediterranean Diets
Miguel A. Martinez-Gonzalez, MD, PhD

The Next Generation of Automated Insulin Delivery Systems for Persons with Type 1 Diabetes — Four New Clinical Trials
U.S. Advanced Hybrid Closed-Loop (AHCL) Pivotal Safety Study
Bruce W. Bode, MD
FLAIR — An NIDDK-Sponsored International, Multi-site Randomized Crossover Trial of AHCL vs. 670G
Richard M. Bergenstal, MD
New Zealand AHCL Randomized Crossover Trial
Martin de Bock, FRACP, PhD
Horizon Automated Glucose Control System Pre-pivotal Trial Data
Bruce A. Buckingham, MD

Biobanks and Electronic Health Records in Diabetes Care and Research
Linking Health Records and the Biobank to Diabetes Discovery Research
Nancy J. Cox, PhD
Biobanks in Diabetes and Obesity Research and Treatment
Dana C. Crawford, PhD
Type 2 Diabetes and Cardiovascular Disease Risk Using Biobank Data
Lawrence S. Phillips, MD

Adipose Innervation
3D Imaging — Visualizing Adipose Tissue Innervation
Paul Cohen, MD, PhD
Central Nervous System Regulation of the Sympathetic Outflow to Brown Adipose Tissue
Shaun Morrison, PhD
Lipid Signals in the Control of Adipose Tissue Innervation
Michael P. Czech, PhD
Regulation of Adipose Sympathetic Plasticity
Wenwen Zeng, PhD

The Best Strategy for Diabetes Remission Using Obesity Treatments Is...
Lifestyle
Sriram Machineni, MD
Pharmacotherapy
Ania M. Jastrzeboff, MD, PhD
Metabolic Surgery
Blandine Laferrère, MD, PhD

4:15 p.m.—6:15 p.m.

Diabetic Foot Management — Care Strategies for the Primary Care and Medical Teams
Diabetic Foot Self-Care Management — Are We Using All the Right Tools?
Timethia Bonner, DPM, PhD
Diabetic Foot Ulcer Pressure Relief — What You Can Do in the Office Today
Ryan T. Crewe, MS, CCRP
Antidiabetic Therapy and Amputation Risk
Michael Fralick, MD, PhD, SM, FRCP
Putting It All Together — Are We Meeting the Mark on Diabetic Foot Ulcer Prevention?
Sicco A. Bus, PhD
• Taking the Technology Plunge — Integrating Digital Technology into Practice
  Diabetes Apps — To Recommend, or Not to Recommend?  
  Rachel Stahl, MS, RD, CDN, CDE  
  Diabetes Care Text Messages — Do They Work?  
  David V. Wagner, PhD  
  Utilizing Personal Health Data — How Much Do We Need, and What Should We Do with It?  
  David Ahn, MD  
  Is Peer Support the Answer for the Technologically Challenged?  
  Michelle L. Litchman, PhD, FNP-BC, APRN

• Expanding the Use of Continuous Glucose Monitoring in Pediatric Settings
  Glucose Monitoring in Stage 2 Type 1 Diabetes  
  Brigitte I. Frohnert, MD, PhD  
  Continuous Glucose Use in Early Stage 3 Type 1 Diabetes  
  Jan Fairchild, FRACP  
  Continuous Glucose Monitor Use in Pediatric Type 2 Diabetes  
  Fida Bacha, MD, FAAP  
  Continuous Glucose Monitor Use in Hospital Settings  
  Gregory P. Forlenza, MD

• Tailoring Treatment Options Based on Diabetes Comorbidities  
  Patients with Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis  
  Kenneth Cusi, MD  
  Patients with Low Estimated Glomerular Filtration Rate  
  George Bakris, MD  
  Patients Post-Stroke/Transient Ischemic Attack  
  Jesse Dawson, MD, BSC (Hons), FRCP, FESO  
  Patients with Heart Failure  
  Silvio E. Inzucchi, MD

• Functional Cure of Type 1 Diabetes — Where Shall We Take the Islet Cells From?  
  The Developmental Biology of Pancreatic Islet Cells  
  Solomon Afelik, PhD  
  How Do Islet Cells Function, and How Can We Measure It?  
  Yong Wang, MD  
  Generation of Human Islet Cells from Stem Cells  
  Matthias Hebrok, PhD  
  Generating New Beta Cells from Adult Human Pancreatic Islets  
  Adolfo Garcia-Ocaña, PhD  
  Islets from Porcine Origin for Diabetes Cell Therapy  
  Gregory Korbutt, PhD

• Bariatric Surgery — What Is New, and What Lessons Have We Learned?  
  Novel Pathophysiology — Remodeling of Muscle and Liver Metabolism  
  Michael Roden, MD  
  Clinical Management of Patients (Adults)  
  Maria Collazo-Clavell, MD  
  Clinical Management of Patients (Youth)  
  Megan M. Kelsey, MD, MS  
  Complications of Bariatric Surgery — Hypoglycemia Pathophysiology and Management  
  Marzieh Salehi, MD, MS  
  Complications of Bariatric Surgery — Effects on Bone  
  Anne Schafer, MD

• Oral Presentations  
  6:30 p.m.-8:30 p.m.
  ADA Networking Reception

SATURDAY, JUNE 13
8:00 a.m.-10:00 a.m.
  Reduction of Hypoglycemia by New Therapies in Clinical Trials — Overestimated, Underestimated, or Both?  
  What the Trials Are Saying — Hypoglycemia Reduction with New Agents  
  Bernard Zinman, OC, MDCM, FRCP, FACP  
  We Need to Know How Often the Glucose Is under 54 mg/dl  
  Simon R. Heller, MD, FRCP  
  We Need to Know How Often the Glucose Is under 70 mg/dl  
  Aaron J. Kowalski, PhD  
  The Constraints of Trial Design Determine Hypoglycemia Outcomes  
  Peter A. Senior, MBBS, PhD

• ADA Education Recognition Program Symposium — Clinical Considerations for Safe, Cultural, Spiritual, and Therapeutic Fasting among People with Diabetes  
  Fasting Practices and Clinical Indications for People with Diabetes  
  Barbara Eichorst, MS, RD, CDNC, CDICES  
  Religious, Cultural, and Health-Related Fasting Strategies and How They Impact Diabetes Outcomes and Care  
  Lorena Drago, MS, RDN, CDN, CDICES  
  Effective Diabetes Self-Management Education and Support for Those Who Fast  
  Joy Pape, MSN, RN, FNP-C, CDICES, FADCES  
  National Survey from People with Diabetes Relating to Why They Fast and What Are Their Expectations from Health Care Providers to Support Their Needs  
  Anna Norton, MS

• Culinary Medicine — Its Role in the Prevention and Treatment of Obesity, Diabetes, and Metabolic Syndrome  
  Overview of Culinary Medicine and Teaching Kitchens as Learning Laboratories  
  David Eisenberg, MD  
  Culinary Medicine during Medical Training and Beyond  
  Michelle Hauser, MD, MS, MPA, FACLM, Chef  
  Culinary Medicine — Translating the Science into Solutions for Type 2 Diabetes Prevention and Management  
  Linda Shiue, MD, Chef

• Can Taxes Alter Dietary Behaviors and Outcomes?  
  When Will a Tax Policy Change Behavior and When Will It Not?  
  Lisa M. Powell, PhD  
  Example from California  
  Dean Schillinger, MD  
  Example from the United Kingdom  
  Martin White, MD, FFPH  
  Example from Mexico  
  Rafael Meza, PhD  
  Example from Philadelphia  
  Christina A. Roberto, PhD

Question and Discussion Period
Speakers and presentation titles are subject to change.
• General Poster Session
11:30 a.m.-1:30 p.m.
• Moderated Poster Discussions/ePoster Theater Sessions
1:45 p.m.-2:40 p.m.
• Debate — The Use of Continuous Glucose Monitoring in Type 2 Diabetes Mellitus — Is There Value? Yes Athena Philis-Tsimikas, MD
No Elbert Huang, MD, MPH, FACP
Rebuttal Athena Philis-Tsimikas, MD
Rebuttal Elbert Huang, MD, MPH, FACP
Question and Discussion Period
1:45 p.m.-3:45 p.m.
• Maximizing Long-Term Weight Loss Maintenance with Lifestyle Changes Overcoming Physiologic Changes from Weight Loss to Achieve Long-Term Weight Loss Maintenance Michael Rosenbaum, MD Critical Psychological, Psychosocial, and Environmental Modifications to Achieve Long-Term Weight Loss Maintenance Colin Greaves, PhD, CPsychol Essential Role of Physical Activity to Achieve Long-Term Weight Loss Maintenance and Implementation Strategies James O. Hill, PhD Evidence-Based Factors and Real-World Models for Success J. Graham Thomas, PhD Question and Discussion Period
• Inpatient Diabetes Care and Education — What Does the Evidence Tell Us? Models for Inpatient Diabetes Education in the Real World Carine M. Nassar, MS, RD, CDE The Ever-Expanding Role of the Pharmacist in the Inpatient Setting Helen A. Habib, PharmD, CDE Can an Inpatient Diabetes Management Service Decrease Length of Stay and Prevent Readmission? Mihail Zilbermint, MD Transitioning Diabetes Patients from Inpatient to Outpatient Pamela C.E. Arnold, MSN, APRN, BC-ADM, CDE
• Joint ADA/ISPAD Symposium — Hemoglobin A1C vs. Time-in-Range as the Primary Metric in Pediatric Diabetes? The Case for A1C as the Primary Metric William E. Winter, MD The Case for Time-in-Range as the Primary Metric Thomas Danne, MD Cognitive Functioning and Decision Making in Teens with Out-Of-Range Glucose Values Rachel M. Wasserman, PhD Practical Strategies to Personalize and Target Time-In-Range in Pediatric Diabetes Daniel DeSalvo, MD
• Lipid Signaling and Lipidomics Nutrient Sensing and Bioenergetics Deborah M. Muoio, PhD Ceramides — The New Cholesterol? Scott A. Summers, PhD Obesity and Metabolic Disease Matthew S. Rodeheffer, PhD Transcriptional Networks Controlling Lipid Metabolism Claudio Villanueva, PhD
• The New Physiology — Organs in a Dish — Promises, Pitfalls, and Potential Clinical Applications State-of-the-Art Lecture — The Promise and Impact of Organoid Medicine Linda G. Griffith, PhD Long-Term Expansion of Pancreatic Islet Organoids from Resident Procr Progenitors Yi Arial Zeng, PhD Organoids to Study Human and Molecular Genetics of Fatty Liver Stefano Romeo, MD, PhD Synergistic Engineering of an Ex Vivo Type 2 Diabetes Model — Organoids and Organs on a Chip John P. Wikswo, Jr., PhD
• Slicing and Dicing — Prohormone Processing in Diabetes Impaired Prohormone Processing in Type 2 Diabetes Steven E. Kahn, MD, ChB Impaired Prohormone Processing in Type 1 Diabetes Emily K. Sims, MD Pro-Islet Amyloid Polypeptide Processing in Diabetes Bruce Verchere, PhD Histologic Analysis of Prohormone Processing Teresa Rodriguez-Calvo, DVM, PhD
• Oral Presentations
• Edwin Bierman Award Lecture Rama Natarajan, PhD, FAHA, FASN Norbert Freinkel Award Lecture David Simmons, MD, MA, FRCP, FACP, FRGS
2:45 p.m.-3:45 p.m.
• Debate — Should the Artificial Pancreas Be Single or Dual Hormone? Single Hormone Roman Hovorka, PhD, FMedSci Dual Hormone Steven J. Russell, MD, PhD Rebuttal Roman Hovorka, PhD, FMedSci Rebuttal Steven J. Russell, MD, PhD Question and Discussion Period
4:00 p.m.-4:55 p.m.
• Debate — Pioglitazone’s Benefits Clearly Outweigh the Risks Yes Vivian Fonseca, MD No Edwin Gale, MB, BChir, FRCP Rebuttal Vivian Fonseca, MD Rebuttal Edwin Gale, MB, BChir, FRCP Question and Discussion Period
4:00 p.m.-5:30 p.m.

- **DAPA-HF Update — Have We Lost SGLT2 Inhibitors to Cardiologists?!**
  - Background and Main Cardiovascular Outcomes
  - John J.V. McMurray, OBE, BSc (Hons), MB, ChB (Hons), MD, FRCP, FESC
  - Patient-Centered Outcomes
  - Mikhail N. Kosiborod, MD
  - Metabolic Outcomes, Diabetes Prevention, and Safety
  - Silvio E. Inzucchi, MD
  - Independent Commentary — Implications for Clinical Care and Future Directions
  - Jeffrey M. Testani, MD, MTR

Question and Discussion Period

4:00 p.m.-6:00 p.m.

- **Dilemmas in Diabetic Foot Infection Management**
  - Diabetic Osteomyelitis When Bone Biopsy Is Not an Option?
  - Katherine M. Raspovic, DPM
  - Effects of Withholding Antibiotics Prior to Bone Biopsy
  - Peter Crisologo, DPM
  - Fungal Diabetic Osteomyelitis — Is It Real?
  - Qeena C. Woodard, DPM, CWS
  - Complications of Long-Term IV Antibiotics — Are We Considering the Risk to Our Patients?
  - Tejal Gandhi, MD

- **Diabetes Devices and Digital Technologies — Who Does It Help the Most (and Least)? (With Richard R. Rubin Award Lecture)**
  - Richard R. Rubin Award Lecture
  - Randi Streisand, PhD, CDE
  - Is One-Size-Fits-All Actually a Bad Approach?
  - Korey K. Hood, PhD
  - Benefits of Device and Tech Use in Tech-Naive and Tech-Underutilizing Populations
  - Jill Weissberg-Benchell, PhD, CDE
  - How Tech May Unintentionally Widen the Health Disparities Gap
  - Lyndsay A. Nelson, PhD
  - Continuous Glucose Monitoring for Those Most Challenged by Diabetes — Why Not?
  - Kimberly P. Spiro, PhD

Question and Discussion Period

- **Myosteatosis — What Happens When Skeletal Muscle Is Marbled Like Steak?**
  - Muscle Quality Matters — Associations between Intermuscular Fat and Muscle Insulin Sensitivity and Mortality Risk
  - Susanna M. Hofmann, MD
  - Impact of Diet, Exercise, Obesity, Aging, and Diabetes on Intermuscular and Subfascial Fat Depots
  - Barbara Gower, PhD
  - Interventions to Favorably Alter Muscle Fat — Where Do We Go From Here?
  - Lisa S. Chow, MD, MS
  - The Athlete’s Paradox — Benign vs. Pathological Skeletal Muscle Lipids
  - Bryan C. Bergman, PhD

- **Diabetes in Sub-Saharan Africa — Challenges and Opportunities**
  - Overview of Diabetes Epidemiology and Complications in Sub-Saharan Africa
  - Jean Claude Mbanya, MD, PhD, MRCP (UK), FRCP (London), FTWAS
  - The Diabetic Foot in Africa — Evidence-Based Strategies to Reduce the Amputation Rate
  - Zulfiquar Ali G. Abbas, MBBS, MMed, DTM&H (UK), FRCP (Glasgow), FRCP (London)
  - Prevention of Type 2 Diabetes in Africa
  - Samuel Dagojogo-Jack, MD, DSc
  - Big Data from Africa — The Human Health and Heredity in Africa (H3Africa) Diabetes Study
  - Ayesha Motala, MB, ChB, MD, FRCP, FCP
  - Transplanting Molecular Diabetology to Africa — The Nigerian Experience
  - Wasiu Gbolahan Balogun, PhD

Question and Discussion Period

- **The Microbiome in Type 1 Diabetes — Where Are We Now?**
  - Development of the Gut Microbiome in Early Childhood
  - Christopher Stewart, PhD
  - What Does the Gut Microbiome Look Like in Type 1 Diabetes?
  - Eric Triplett, PhD, MS, BS
  - Manipulating the Gut Microbiome to Treat Diabetes
  - Emma Hamilton-Williams, PhD
  - Fecal Transplantation for Type 1 Diabetes
  - Max Nieuwodorp, MD, PhD

- **Immunity, Metabolism, and Diabetes**
  - Adipose Macrophage and Metabolic Homeostasis
  - Carey N. Lumeng, MD, PhD
  - Regulation of Adipose Inflammation by Metabolic Endoplasmic Reticulum Stress
  - Yong Liu, PhD
  - Sympathetic-Associated Macrophages in Energy Homeostasis
  - Ana Domingos, PhD
  - Th17-Mediated Inflammation and Type 2 Diabetes
  - Barbara Nikolajczyk, PhD

- **Orchestrating the Islet — Structural and Functional Interactions**
  - Building an Islet — Location, Location, Location!
  - Barak Blum, PhD
  - The Elusive Delta Cell — Mechanisms Underlying Somatostatin Release
  - Quan Zhang, PhD
  - Gently Does It — Studying the Unperturbed Alpha Cell in Pancreas Slices
  - Herbert Y. Gaisano, MD, BSc, FRCP
  - Pericytes and the Microvasculature in Islet Function
  - Joana Almaca, PhD

**Returning Genetic Evidence in Monogenic Diabetes**
- Siri Atma W. Greetley, MD, PhD
- Implementing the Return of Genetic Results in Diabetes Practice
- Toni I. Pollin, MS, PhD, CGC

**Returning Genetic Results to the Patient with Diabetes**
- Genetic Variation and Defining Individual Risk
- Wendy K. Chung, MD, PhD
- Returning Incidental Findings in Genomic Research in Diverse Populations
- Adolfo Correa, MD, PhD

**Implementing the Return of Genetic Results in Diabetes Practice**
- Toni I. Pollin, MS, PhD, CGC
5:00 p.m.-6:00 p.m.

• Debate — Is There a Current Place for Sulfonylureas in the Treatment of Type 2 Diabetes?
  Yes
  Sophia Zoungas, MBBS (Hons), PhD, FRACP
  No
  Carol H. Wysham, MD
  Rebuttal
  Sophia Zoungas, MBBS (Hons), PhD, FRACP
  Rebuttal
  Carol H. Wysham, MD
  Question and Discussion Period

• Oral Presentations

SUNDAY, JUNE 14

8:00 a.m.-10:00 a.m.

• Cardiorenal–Metabolic Axis in Diabetes
  Pathophysiology of Cardiorenal Syndrome
  Peter A. McCullough, MD, MPH
  Review of a Landmark Trial Focusing on Cardiovascular Outcomes (DAPA-HF)
  Biykem Bozkurt, MD, PhD, FHFSA, FACC, FAHA
  Review of a Landmark Trial Focusing on Renal Outcomes (CREDENCE)
  Katherine R. Tuttle, MD, FACP, FASN, FNKF
  Review Evidence Base Evaluating Impact of Blood Pressure, Lipid, and Glycemic Control on Cardiovascular Outcomes
  Melissa L. Magwire, RN, MSN, CDE
  Translating Evidence to Practice
  Jennifer B. Green, MD
  Question and Discussion Period

• Lifestyle Interventions for Type 2 Diabetes Remission
  The DiRECT Trial and Very-Low-Calorie Eating Plans
  Alison C. Barnes, RD
  Low-Carbohydrate Eating Plans
  William S. Yancy, Jr., MD, MHS
  High-Fiber Diets and Plant-Based Eating Plans for Treating Type 2 Diabetes
  Hana Kahleova, MD, PhD, MBA
  Exercise Alone, or Is It a Combination of Diet and Exercise?
  Kristian Karstoft, MD, PhD, DMSc
  Question and Discussion Period

• Adjunctive Glucose-Lowering Therapies for Adults with Type 1 Diabetes — Evidence
  Metformin
  Irene Hramiak, MD, FRCP(C), FACP
  GLP-1 Receptor Agonists
  Tina Vilseboll, MD, DMSc
  SGLT2’s
  Chantal Mathieu, MD, PhD
  Question and Discussion Period

• ADA Diabetes Symposium — Unraveling the Heterogeneity in Type 2 Diabetes
  Subtypes of Type 2 Diabetes Determined from Clinical Parameters
  Emma Ahlqvist, PhD
  Precision Medicine in Type 2 Diabetes — Using Individualized Prediction Models to Optimize Selection of Treatment
  John M. Dennis
  Using Genetic Risk Scores to Distinguish Subtypes of Type 2 Diabetes
  Anubha Mahajan, PhD
  Defining Heterogeneity among Women with Gestational Diabetes
  Camille E. Powe, MD

• NIDDK Symposium — Spanning from Genes to Improving Clinical Care across Translational Valleys
  From Single Nucleotide Polymorphisms to Drug Targets — How the Accelerating Medicines Partnership Type 2 Diabetes Is Using Big Data to Understand Diabetes
  Karen L. Mohlke, PhD
  Integrating Multi-omic and Genome-Wide Cellular Datasets to Unlock Mechanisms for Islet Dysfunction in Type 2 Diabetes
  Anna L. Gloyn, DPhil
  Beyond Histology and Urine — Helping Kidney Patients Find Precision Medicine
  Evren U. Azeloglu, PhD
  Right Data, Right Patient, Right Time — Improving Interoperability of Health Data for Research and Care
  Jenna M. Norton, MPH

• Pancreas Transplantation — Why Aren’t We Doing More?
  Patient Selection for Pancreas and Islet Transplantation
  Meaghan Stumpf, MD
  Long-Term Immunosuppression in Pancreas Transplant Patients
  Maya Campara, PharmD
  Glycemic Management after Pancreas Transplantation for Recipients with Type 1 and Type 2 Diabetes
  Michael R. Rickels, MD, MS
  Current Clinical Results in Pancreas Transplantation for Type 1 and Type 2 Diabetes
  Angelika Grussner, PhD
  Question and Discussion Period

• Effect of Metabolic Stress on Insulin Action
  Role of Hypoxia in Mediating Metabolic Improvements
  Isha Jain, PhD
  Molecular Benefits of Exercise in Countering Metabolic Stress
  Juleen R. Zierath, PhD
  Metabolic Regulation of Cell Fate Decisions
  Lydia Finley, PhD
  Insulin Resistance Is a Consequence of a Canonical Mitochondrial Stress Response Pathway
  David E. James, FAA

• Mind the Clock — Timing of Feeding in the Control of Metabolic Health
  Meal Timing in Health and Disease
  Satchidananda Panda, PhD
  Insulin Sensitization — Alternate Day Fasting vs. Caloric Restriction
  Krista Varady, PhD
  Synching Tissue Clocks with Feeding to Improve Metabolic Health
  Paolo Sassone-Corsi, PhD
  Meal Timing — Influence on Behavior and Metabolism
  Eric Ravussin, PhD

• The Islet under Duress in Type 1 Diabetes
  State of the Field — The Islets in Dialogue with the Immune System in Type 1 Diabetes
  Decio L. Eizirik, MD, PhD
  Monogenic Forms of Autoimmune Diabetes
  Sarah E. Flanagan, PhD
Beta-Cell Endoplasmic Reticulum Stress in Type 1 Diabetes
Feyza Engin, PhD

Novel Imaging Techniques to Detect Islet Inflammation
Richard KP Benninger, PhD

Oral Presentations
10:15 a.m.-11:45 a.m.

• President, Medicine & Science Address
Robert H. Eckel, MD

• Banting Medal for Scientific Achievement
Ele Ferrannini, MD

12:00 p.m.-1:00 p.m.

• Professional Interest Group Discussion on Diabetes and Cardiovascular Disease — Hot Topics in Diabetes Cardiovascular Disease Management
Excess Heart Failure and Cardiovascular Risk in Women with Diabetes — A Not-So-Sweet Truth
William B. Horton, MD, FACP

• Professional Interest Group Discussion on Eye Health — Common Questions Encountered by Diabetes Care Providers Related to Eye Issues Experienced by People with Diabetes
Common Ocular Symptoms and Questions Encountered by Primary Care Providers, Diabetes Education Specialists, and Diabetologists
Richard M. Calderon, OD, FAAO
Aids That Can Help Patients with Low Vision
Richard J. Shulder, OD, FAAO, FIALVS

• Professional Interest Group Discussion on Behavioral Medicine and Psychology — The Value Proposition for Behavioral Health — Examples of Effectively Making the Case
What an Administrator Can Do to Advocate for Behavioral Health
Andrew Ahmann, MD

1:00 p.m.-2:00 p.m.

• Professional Interest Group Discussion on Diabetes Self-Management Education and Support (DSMES) — Focus on 2020 DSMES Consensus Report
Advancing Access to DSMES
Clipper F. Young, PharmD, MPH, CDE, BC-ADM, BCGP
2020 DSMES Consensus Report — Role of DSMES in Today’s Health Care Environment
Margaret A. Powers, PhD, RD, CDE
Call to Action — Recommendations and the Four Critical Times
Joan K. Bardsley, MBA, BSN, RN, CDE, FAADE

• Women’s Interprofessional Network of the ADA (WIN ADA) — Finding Equilibrium — Re-thinking “Work Life Balance” to Maintain Personal Wellness
Strategies to Optimize Work-Life Integration
Linda DiMeglio, MD, MPH
Recognizing and Recovering from Professional Burnout
Mary de Groot, PhD

• Professional Interest Group Discussion on Diabetes in Youth — “Do-It-Yourself”/“Do-It-Together” (DIY/DIT) Closed-Loop Systems in Youth
Do-It-Yourself/Do-It-Together
Rayhan Lal, MD
Psychosocial/Behavioral Impact of DIY/DIT in Youth
Diana Naranjo, PhD
DIY/DIT in the Childcare, School, and Camp Setting
Anastasia Albanese-O’Neill, PhD, APRN, CDE

1:00 p.m.-2:00 p.m.

• New Insights from the Restoring Insulin Secretion (RISE) Study — Differences between Adults and Youth with Prediabetes and Type 2 Diabetes
Looking Back — What Have We Already Learned?
Sharon Edelstein, ScM

• Alpha-Cell Function
Thomas A. Buchanan, MD
Proinsulin and the Beta Cell
Kristina Utschneider, MD
Looking Forward — What More Do We Need to Know?
Kristen J. Nadeau, MD, MS

• General Poster Session/Moderated Poster Discussions/ePoster Theater Sessions
1:00 p.m.-2:00 p.m.

• Session Break (Take this opportunity to visit the Exhibit and Poster Halls)

2:15 p.m.-3:00 p.m.

• Kelly West Award for Outstanding Achievement in Epidemiology Lecture
Elizabeth Selvin, PhD, MPH

2:15 p.m.-3:15 p.m.

• Verifying a Strategic, Initial Combination Approach to Diabetes Management
Introduction to the Paradigm Shift and Recap of the Main VERIFY Results
Päivi M. Paldánius, MMEd, PhD
Impact of Novel Treatment Strategy on Alpha-Cell Functionality and Its Ramifications on Time to Insulin
David R. Matthews, DPhil, FRCP
Safety and Tolerability of Initial Combination Strategy
Chantal Mathieu, MD, PhD
Early Combination Treatment Strategy for All Newly Diagnosed Type 2 Diabetes Mellitus?
Stefano Del Prato, MD

Question and Discussion Period
2:15 p.m.-4:15 p.m.

- Update on Lipid-Lowering Drugs
  How to Diagnose, Avoid, and Treat the Side Effects of Statin Therapy
  Connie B. Newman, MD, FACP, FAHA, FAMWA
  Omega-3 Fatty Acids — Should More of Our Patients Be Treated with Fish Oil?
  Deepak L. Bhatt, MD, MPH, FACC, FAHA, FSCAI, FESC
  PCSK9 Inhibitors — When Should You Use These Agents?
  Jennifer G. Robinson, MD, MPH

- New Perspectives on Diabetic Retinopathy Diagnosis and Treatment
  Retinal Neurodegeneration in Diabetes
  Rafael Simó, MD, PhD
  Autonomous Artificial Intelligence for Diagnosis of Diabetic Retinopathy
  Michael D. Abràmoff, MD, PhD
  Lessons from Recent Trials and Practice
  Donald S. Fong, MD
  Genetic Aspects of Diabetic Retinopathy
  Lucia Sobrin, MD, MPH

- Reaching the Hard to Reach — Real-World Stories
  A Day in the Life of Emerging Adults with Type 1 Diabetes Mellitus
  Neesha Ramchandani, PhD, PNP, CDCA, CDCES
  Helping the Homeless Manage Diabetes
  Rana Malek, MD
  Juggling Diabetes Self-Care Post-Kidney Transplant
  Della Connor, PhD, RN, FNP-BC, FNKF
  Living with Diabetes after Amputation
  Gary M. Rothenberg, DPM, CDE, CWS

- Strength-Based Approaches in Diabetes Care — Challenging the Deficit Model
  What Teens with Type 1 Do RIGHT — Equipping Parents and Providers to Build Youths’ Diabetes Strengths
  Marisa E. Hilliard, PhD
  Promoting Resilience Resources in Distressed Teens
  Joyce Yi-Frazier, PhD

- Low-Carb Diets in Pediatric Type 1 Diabetes — Pros and Cons
  Low-Carb Diets in Pediatric Type 1 Diabetes — Pros
  Belinda S. Lennerz, MD, PhD
  Low-Carb Diets in Pediatric Type 1 Diabetes — Cons
  Carmel E. Smith, RD, PhD
  Behavioral and Psychosocial Aspects of Low-Carb Diets in Pediatric Diabetes
  Katherine A. Gallagher, PhD
  Psychosocial Implications of Low-Carb Diets and Disordered Eating in Pediatric Diabetes
  Claire Aarnio-Peterson, PhD

- Joint ADA/Diabetes UK Symposium — Islet Transplantation — Quo Vadis?
  Current Outcomes in Islet-Cell Transplantation
  Franca B. Barton, MS
  National Health Service Islet Transplant Network — How We Made It Work for the UK
  Sarah Cross, PhD
  National Coverage Determination for Islet-Cell Transplantation — Can We Make It Work in the U.S.?
  TBD
  What Do Patients Expect from a Cell-Based Therapy of Diabetes?
  Rebecca S. Monson, MD, MPH
  Health Economics of Islet-Cell Transplantation and Diabetes Therapy
  Andrew M. Posselt, MD, PhD
  FDA Center for Biologics Evaluation and Research Perspective on Cell Therapies for Diabetes
  Ilan Irony, MD

- Not Your Grandmother’s Transcription Factors — New Insights into Genomic Regulation of Beta-Cell Function
  RNA Methylation in the Pancreatic Beta Cell
  Rohit Kulkarni, MD, PhD
  Non-coding RNAs in the Control of Pancreatic β-Cell Function and Development
  Romano Regazzi, PhD
  Chromatin Remodeling Complexes and Transcriptional Regulation of Beta-Cell Development and Function
  Jason Spaeth, PhD
  Lost in Translation — Illuminating Pathways of mRNA Translation in the Beta Cell
  Doris A. Stoffers, MD, PhD

- Oral Presentations

4:30 p.m.-6:00 p.m.

- Physiological Mechanisms of Remission of Type 2 Diabetes
  Defining Remission of Type 2 Diabetes — What Does This Mean to the Patient and Provider?
  William T. Cefalu, MD
  The How and Why of Nonsurgical Weight-Loss-Induced Remission of Type 2 Diabetes
  Roy Taylor, MD
  Long-Term Remission of Type 2 Diabetes following Bariatric Surgery
  Francesco Rubino, MD
  Panel Discussion — Remission of Type 2 Diabetes — Fact or Fiction?

4:30 p.m.-6:30 p.m.

- Joint ADA/ASN Symposium — Targeting Diabetic Kidney Disease (DKD) — Are We Ready for Precision Medicine Trials?
  Molecular Mechanism of DKD — More Than One Disease?
  Tobias B. Huber, MD
  Identifying Noninvasive Treatment Response Biomarkers for Patient Stratification
  Wenjun Ju, PhD
  Developing a Path Forward for Innovative Trial Design in DKD — A Regulator’s Perspective
  Peter Mol, PhD, PharmD
  Implementation of Precision Medicine Trials in DKD
  Hiddo L. Heerspink, PhD
• Debate — Reconciling Guideline Recommendations for Cardiovascular Risk and Disease Management in Type 2 Diabetes Should Blood Pressure Target for all Individuals with Type 2 Diabetes and Hypertension Be <130/80 mmHg? Yes, as Recommended by the 2017 ACC/AHA Guidelines Paul K. Whelton, MB, MD, MSc No, It Depends on Underlying Risk and whether It Can Be Safely Attained as Recommended by the 2019 ADA Standards of Care Raymond Townsend, MD Question and Discussion Period

Should Metformin Be Considered First-Line Therapy for Individuals with Type 2 Diabetes with Established Arteriosclerotic Cardiovascular Disease (ASCVD) or at High Risk for ASCVD? No Longer Justified, per the 2019 ESC/EASD Recommendations Francesco Consentino, MD, PhD, FESC Yes, It Is Time Tested and Proven, as Recommended by the 2019 ADA Standards of Care Melanie J. Davies, CBE, MB, ChB, MD, FRCP, FRCGP Question and Discussion Period

What Will Be the Impact of Proposed Health Policy Changes on Diabetes Care? Current Status of the Affordable Care Act Jean O’Connor, JD, MPH, DrPH, FACHE Coverage for Preexisting Conditions and Essential Medications Kasia J. Lipska, MD, MHS, BS The Future of Medicaid Rebecca Myerson, MPH, PhD Commercial Health Insurance and the Expansion of High-Deductible Health Plans J. Frank Wharam, MD, MPH

• Menopause and Diabetes Effects of Diabetes on Ovarian Aging Melissa F. Wellons, MD Vasomotor Symptoms and Diabetes Risk Kristen E. Gray, PhD Effects of Diabetes on Menopause Onset and Symptoms and Osteoporosis Sarit Polsky, MD, MPH Novel Treatments to Improve B-Cell Function in Obese Menopausal Women Dragana Lovre, MD Associations of Steroid Sex Hormones Type 2 Diabetes Risk in Women Taulant Muka, MD, MPH, PhD Question and Discussion Period


Nonalcoholic Steatohepatitis (NASH) — Emerging Concepts and Opportunities New Insights into Liver Macrophages in NASH Pathogenesis Frank Tacke, MD, PhD Inflammation and Cell Death in NASH Laura Nagy, PhD Gating NASH Progression by Brown Adipose Thermogenesis Liangyou Rui, PhD Novel Mechanisms and Therapeutic Opportunities in Liver Fibrosis in NASH Ira Tabas, MD, PhD

Oral Presentations Roger Pecoraro Award Lecture Lee J. Sanders, DPM

• Addressing Care Gaps — New Frontiers for Diabetes Nutrition Providers and Services REAL HEALTH Diabetes — Translating Look AHEAD into Usual Care at Community Health Centers Linda M. Delahanty, MS, RDN Expanding Access to Nutrition and Diabetes Education through Innovative Technology Jodi S. Krall, PhD A New Era — Leveraging RDNs in Medication Management in Reducing Therapeutic Inertia Gretchen Benson, RDN, CDE Food Is Medicine — Prescribing Food as a Specialty Drug for Food-Insecure People with Diabetes Michelle Passaretti, MSN, BSN, RN, CCM

Utilizing Diabetes Technology in the Real World — Tools of the Trade Innovative Models that Educate Patients and Care Teams on Continuous Glucose Monitoring Use Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES Continuous Glucose Monitoring — Using Trend Arrows as a Road Map to Increase Time-in-Range Jeniece T. Ilkowitz, MA, BSN, RN, CDE Educating Patients to Succeed with Advanced Pump Therapy Laurel H. Messer, RN, PhD, CDE The Do-It-Yourself Movement — How Do We Manage Patients That Are Looping? Julia Blanchette, PhD, RN, CDCES

How Do GLP-1 Receptor Agonists Provide Cardioprotection? GLP-1 Receptor Agonists and Cardiovascular Outcomes — The Evidence Mansoor Husain, MD, FRCPC GLP-1 and Atherosclerosis-Direct and Indirect Mechanisms Sanjay Rajagopalan, MD GLP-1 and Cardioprotection — Where Are the Cellular Targets? Daniel J. Drucker, MD Question and Discussion Period
• Joint ADA/AACC Symposium —
Point-of-Care HbA1c — Should We Use It to Diagnose Diabetes?
Point-of-Care HbA1c — How Does It Differ from a Laboratory Assay?
Randie R. Little, PhD

How the FDA Decides whether to Clear an HbA1c Device (Point-of-Care or Nonlaboratory) for Diagnosis
Julianne C. Lessard, PhD

We Should Not Use Point-of-Care HbA1c to Diagnose Diabetes
David B. Sacks, MB, ChB

• Update from the TEDDY Study
Determinants of Islet Autoimmunity and Clinical Implications
Marian Rewers, MD, PhD

Metabolome Signals in the TEDDY Study
Qian Li, PhD

HbA1c — Is It a Good Diagnostic Predictor of Type 1 Onset in a Pediatric Population?
Kendra Vehik, PhD, MPH

Dissecting the Type 1 Diabetes and Celiac Disease Overlap in the TEDDY Study
William Hagopian, MD, PhD

• From Genome-Wide Association Studies to Multiomics — Defining Diabetes Risk and Clinical Relevance
Diabetes Research Using Biobanks and Multiomics Technologies
Guillaume Pare, MD

Multiomic Approaches in Explaining Diabetes Risk
Praveen Sethupathy, PhD

Epigenomics and Risk of Type 2 Diabetes
Kyle J. Gaulton, PhD

Epigenomics and Risk of Gestational Diabetes
Marie-France Hivert, MD, MMSc

• Joint ADA/EASD Symposium —
Leveraging Metabolism to Prevent, Treat, or Cure Type 1 Diabetes
Treatment — Closed-Loop Trials in the U.S.
R. Paul Wadwa, MD

Treatment — Closed-Loop Trials in Europe
Charlotte K. Boughton, MRCP, PhD

Prevention — Oral Insulin in Toddlers with Genetic Risk of Type 1 Diabetes Pan European Trial
Olga Kordonouri, PhD

Commentary on the Future of Type 1 Diabetes Management — Treatment or Cure? Closed-Loop Trials, Immunomodulation, or Both?
Jay S. Skylan, MD, MACP

• Oral Presentations
10:10 a.m.-11:45 a.m.

National Scientific & Health Care Achievement Awards Presentation

Outstanding Scientific Achievement Award Lecture
Jiandie Lin, PhD

12:00 p.m.-1:00 p.m.

Professional Interest Group Discussion on Diabetes Technology — Interpreting Time-in-Range in Different Populations and Situations
Time-in-Range as a Research Outcome Measure
John R. Petrie, PhD, FRCP

Interpreting Time-in-Range during Pregnancy
Viral Shah, MD

Interpreting Time-in-Range in Children
Jenise C. Wong, MD, PhD

Utilizing Time-in-Range for Pre-Op Clearance
Joseph A. Aloj, MD

Question and Discussion Period

• Professional Interest Group Discussion on Health Care Delivery and Quality Improvement —
Leveraging Population Health Methods to Improve Diabetes Care
Implementing the Lessons of the Diabetes Prevention Program
Ronald T. Ackermann, MD, MPH

Tannaz Moin, MD, MBA, MSHS

Improving Population Health in Underserved Communities with Type 2 Diabetes
Athena Philis-Tsimikas, MD

• Professional Interest Group Discussion on Pregnancy and Reproductive Health — All Pregnant Women with Preexisting Diabetes Should Take Low-Dose Aspirin to Prevent Preeclampsia
Pro
Fionnuala Breathnach, MD, MRCOG, FRCP, DCH, DipGUMed

Con
Ellen W. Seely, MD

• Professional Interest Group Discussion on Public Health and Epidemiology — Diabetes and Built Environment
Welcome and Michaela Modan Memorial Award Presentation
Hsin-Chieh “Jessica” Yeh, PhD

Built Environment and Diabetes Risks and Related Outcomes
Gillian Booth, MD, MSc

Built Environment and Disadvantaged Communities
Tiffany L. Gary-Webb, PhD, MHS

• Professional Interest Group Discussion on Immunology, Immunogenetics, and Transplantation — Next Generation in Immunotherapy in Type 1 Diabetes
Immunomodulation Followed by Antigen-Specific T(reg) Infusion Controls Islet Autoimmunity
Allison L. Bayer, PhD

Extending Remission and Reversing New-Onset Type 1 Diabetes by Targeted Ablation of Autoreactive T-Cells
Kaitlin Carroll, PhD
Altered Function of Antigen-Presenting Cells in Type 1 Diabetes — A Challenge for Antigen-Specific Immunotherapy?
Jorge Postigo Fernandez, PhD

Question and Discussion Period

• General Poster Session/Moderated Poster Sessions/ePoster Theater Sessions

1:00 p.m.-2:00 p.m.

• Session Break (Take this opportunity to visit the Exhibit and Poster Halls)

2:15 p.m.-3:10 p.m.

• Debate — Primary Cardiovascular Prevention with SGLT2 Inhibitors or GLP-1 Receptor Agonists — Are We Ready for Prime Time?
  Yes, We Are Ready for Prime Time
  Mikhail N. Kosiborod, MD
  No, We Are Not Ready for Prime Time
  Darren K. McGuire, MD, MHSc
  Rebuttal
  Mikhail N. Kosiborod, MD
  Rebuttal
  Darren K. McGuire, MD, MHSc

Question and Discussion Period

2:15 p.m.-4:15 p.m.

• Hypoglycemia — All about the Brain
  Central Mechanisms of Hypoglycemia Awareness
  Rory J. McCrimmon, MD
  Brain Imaging in Hypoglycemia — How Does It Relate to Clinical Practice?
  Pratik Choudhary, PhD
  Cognitions and Beliefs That Increase Hypoglycemia Risk
  Linda Gonder-Frederick, PhD
  Personality and Hypoglycemia Risk
  Therese C. Anderbro, PhD

• Disparities in Diabetes and Diabetes Care — What Can We Do about It?
  Disparities in Care Delivery in Diabetes — Strategies for Underrepresented and Underserved Young Adults
  Shivani Agarwal, MD
  Patient-Centered Approaches to Addressing Latino Diabetes Disparities
  Arshiya A. Baig, MD, MPH
  Community and Family-Based Strategies to Improve Type 1 Diabetes Management in African American and Latino School-Aged Children
  Ashley Butler, PhD

Translating Diabetes Self-Management Support to Reach Socioeconomically Disadvantaged and Ethnic Minority Adults with Type 2 Diabetes
Jeffrey S. Gonzalez, PhD

Innovative Approaches to Address Disparities in African Americans with Type 2 Diabetes — An Important Role for Pastors and Church Leaders
Elizabeth Lynch, PhD

Question and Discussion Period

• Physical Activity and Diabetes — When, How Much, Insulin Adjustments, and More
  Exercise Timing Matters, or Does It?
  When to Be Active
  Jane E. Yardley, PhD
  Exercise Volume Considerations for Type 2 Diabetes
  Normand G. Boulez, PhD
  Can Insulin Be Optimally Managed for Exercise? How to Adjust Dosing
  Rémi Rabasa-Lloret, MD, PhD
  Have Diabetic Feet? How to Use New Technologies to Manage Activity
  David G. Armstrong, DPM, MD, PhD

• Artificial Intelligence (AI), Machine Learning, and Diabetes
  What Is AI?
  TBD
  AI for Risk Assessment and Blood Glucose Control
  Josep Vehi, PhD
  Use of AI to Tailor Medical Therapy for Type 2 Diabetes (Precision Medicine)
  Adrian Aguilera, PhD
  Use of AI to Screen for Complications
  Arianna Dagliati, PhD

• Fetal Sex and Pregnancy Outcomes
  Maternal Diabetes and Sex of the Offspring
  Samantha F. Ehrlich, PhD, MPH
  Fetal Sex Influences Maternal Diabetes Risk and Pregnancy Complications
  Claire T. Roberts, BA, BSc (Hons), PhD
  Sex Differences in Prenatal Programming of Metabolic Syndrome — Role of Maternal-Fetal Androgens in Pregnancy
  Grace Huang, MD
  Sex Differences in Metabolic Programming by Maternal Obesity
  Susan Ozanne, PhD

Chinese Diabetes Society Symposium — Novel Antidiabetic Approaches and Potential Targets
Guangwei Li, MD

The Antidiabetic Effect of Dorzagliatin in Chinese Patients with Type 2 Diabetes
Dalong Zhu, MD, PhD

Diabetes Originates from the Liver
Xiaoqing Li, MD, PhD

Nutrient Sensing and Metabolic Regulation in the Liver
Yu Li, PhD

• Twenty Years of Pediatric Diabetes Surveillance — What Do We Know and Why It Matters — The SEARCH for Diabetes in Youth Study
  The Changing Landscape of Pediatric Diabetes in the U.S.
  Jean M. Lawrence, ScD, MPH, MSSA
  Disparities in Morbidity and Mortality Associated with Pediatric Diabetes
  Amy K. Mottl, MD, MPH, FASN
  Psychosocial and Behavioral Correlates of Pediatric Diabetes
  Katherine A. Sauder, PhD
  Barriers to Care, Cost, and Care Transitions
  Catherine Pihoker, MD

• The Human Pancreas in Type 1 Diabetes
  Heterogeneity in the Type 1 Diabetes Pancreas
  Mark A. Atkinson, PhD
  Loss of Endocrine and Exocrine Mass in Type 1 Diabetes
  Martha Campbell-Thompson, DVM, PhD
  Beta Cells Releasing Information
  Anath Shalev, MD
  T-Cells in the Islets — What Do They See?
  Maki Nakayama, MD, PhD

CHICAGO | JUNE 12-16, 2020 | #ADA2020

Speakers and presentation titles are subject to change.
• **Inter-organ Cross Talk in Physiology and Metabolic Disease**
  Role of the Nervous System in Mediating the Physiology and Pharmacology of FGF21
  Steven Kliewer, PhD
  The Role of Exosomes in Mediating Inter-organ Cross Talk
  Ilihiro Shimomura, MD
  Inter-organ Effects Mediating the Beneficial Effects of Exercise on Metabolism
  Laurie J. Goodyear, PhD
  Lipids as Mediators of Inter-organ Cross Talk in Metabolism
  Judith Simcox, BA, PhD

  3:15 p.m.-4:15 p.m.
  • **Weekly Basal Insulin — The Wave of the Future?**
    Do We Need Even Longer-Acting Basal Insulin Analogs?
    Philip Home, DM, DPhil
    Novel Pharmacological Strategies to Develop Weekly Insulin
    J. Hans DeVries, MD, PhD
    Weekly Basal Insulin Analogs — Clinical Evidence So Far!
    Stefano Del Prato, MD
  • **Oral Presentations**

  4:30 p.m.-6:30 p.m.
  • **Novel Approaches for Cell and Tissue Interrogation — Using the Kidney as a Model**
    The Value of Kidney Biopsies to Empower New Discoveries in Diabetic Kidney Disease
    Matthias Kretzler, MD
    Linking Structure to Function in Early Diabetic Kidney Disease via Single Cell Analysis in Renal Biopsy Cohorts
    Rajasree Menon, PhD
    Visualizing Diabetic Kidney Disease Damage by 3D Multifluorescence Biopsy Imaging
    Tarek Ashkar (El-Achkar), MD
    Interrogation of Kidney Disease with Spatial Transcriptomics
    Jamie Marshall, PhD
    Lessons from Single Cell Genomics and Kidney Organoids
    Anna Greka, MD, PhD
  • **Perspectives on the Future of Precision Diabetes Medicine — A Joint ADA/EASD Symposium**
    Optimizing Precision Medicine in Diabetes Using Monogenic Testing
    Andrew T. Hattersley, FRCP, DM
    How Can We Better Target Treatment to Lower HbA1c in Patients with Type 2 Diabetes?
    Ewan Pearson, PhD
    Translating Evidence into Practice — Pros and Cons of a Precision-Medicine Approach to Diabetes and Obesity
    Wendy K. Chung, MD, PhD
    Are Precision Medicine-Based Diabetes Guidelines Translatable across Populations?
    James B. Meigs, MD, MPH
  • **The Year in Review — Highlights of the Past Year in Basic, Translational, and Clinical Science**
    Basic Science
    Alan Sattel, PhD
    Translational Science
    Lora K. Heisler, PhD
    Clinical Science
    David M. Nathan, MD
  • **Interpreting Cardiovascular Outcomes Trials — Implications for Practice**
    Which Medication Is Best to Prevent a Cardiovascular Event in a Patient with Type 2 Diabetes and Established or at High Risk for Heart Disease?
    Yehuda Handelsman, MD
    Case Presentation
    Yehuda Handelsman, MD
    Choosing a GLP-1 Receptor Agonist
    Ofrin Mosenzon, MD, MSc
    Choosing an SGLT2 Inhibitor
    Sunder Mudalair, MD
    Choosing a PCSK9 Inhibitor
    Christopher Cannon, MD
    Choosing a Fish Oil
    Sergio Fazio, MD, PhD
    Panel Discussion — Choosing the “Winning” Medication
  • **Cognitive Function in Obesity and Appetite Regulation**
    The Bidirectional Relationship between Obesity and Executive Function
    Luke E. Stoeckel, PhD
    The Role of Cognitive Function on Obesity Treatment Success — Predictor, Outcome, or Both?
    Misty A.W. Hawkins, PhD
    This Is Your Brain on Food — Food as an Addictive Substance
    Ashley N. Gearhardt, PhD
  • **It’s All in the Timing — Time and Age-Related Changes in Islet Function**
    Type 2 Diabetes in Youth — A Different Disease?
    Tamara S. Hannon, MD, MS
    Age-Related Metabolic Rewiring of Pancreatic β-Cell Function
    Matthew Wortham, PhD
    Time Zones of Pancreatic Islet Metabolism
    Charna Dibner, PhD
    Role of Islet Circadian Clock in Beta-Cell Maturation and Function
    Aleksey Matveyenko, PhD
  • **Oral Presentations**
8:00 a.m.-10:00 a.m.

- Diabetes Meets the Sandman—Sleep, Diabetes, and Glycemic Management
  Which Comes First—Poor Sleep or Poor Glycemic Control?
  Susana R. Patton, PhD
  Mechanisms Linking Sleep to Glycemic Control
  Erin C. Hanlon, PhD
  Addressing Zzz's in Diabetes Management
  Michelle Perfect, PhD
  Technology and Overnight Diabetes Management—Is Nighttime Still the Worst Time?
  Michelle A. Van Name, MD
  To Sleep or Not to Sleep? That Is the Question for Youth with Type 1 Diabetes
  Sarah S. Jaser, PhD
  Question and Discussion Period

- SGLT2 Inhibitors — How Do They Reduce Cardiorenal Disease?
  It is a Metabolic Mediation
  Ele Ferrannini, MD
  Primary Effect Is in the Heart
  Subodh Verma, MD, PhD, FRCSC
  Primary Effect Is in the Kidney
  David Cherney, MD, PhD
  Question and Discussion Period

- New Data on Clinical Outcomes from the Diabetes Prevention Program Outcomes Study (DPPOS)
  Overview of the DPPOS
  David M. Nathan, MD
  Microvascular Complications
  Mark Molitch, MD
  Metformin and Lifestyle Effects on Cardiovascular Events
  Ronald B. Goldberg, MD
  Metformin and Lifestyle Effects on Cancer Incidence
  Brandy M. Heckman-Stoddard, PhD, MPH
  Age-Sensitive Outcomes in the DPPOS
  Jose A. Luchsinger-Stuart, MD, MPH
  Immune Intervention During the Stages of Type 1 Diabetes Development — Type 1 Diabetes TrialNet
  Progressing through the Stages of Type 1 Diabetes
  Diane K. Wherrett, MD, FRCPC
  The Anti-CD3 Antibody Teplizumab Delays Type 1 Diabetes Onset in Stage 2 Type 1 Diabetes—Responder Characteristics
  S. Alice Long, PhD
  Response to Low-Dose Anti-thymocyte Globulin in Stage 3 Type 1 Diabetes
  Laura M. Jacobsen, MD
  Question and Discussion Period

- Economic Drivers of Obesity Treatment — From Individuals to Systems
  Economic Impacts of Treating Obesity
  Amy E. Rothberg, MD, PhD
  Overcoming Economic Barriers to Treating Obesity
  Kimberly Guzdune, MD, MPH, FTOS
  Cost-Effective Models of Care for Obesity Treatment
  Bartolome Burguera, MD, PhD
  Clinical Assessment of Social Determinants of Health in Patients with Obesity
  Monica E. Peek, MD, MPH, MSc
  What’s New with GLP-1?
  Role of Incretins in Glucose Homeostasis
  Filip K. Knop, MD, PhD
  Bariatric Surgery and a New Pathway in the Regulation of Alpha Cell GLP-1
  Bethany Cummings, DVM, PhD
  Neprilysin — An Underappreciated Player in GLP-1 Action
  Sakeneh Zraika, PhD
  The Role of Alpha-Cell GLP-1 in Physiology and Stress
  Darleen A. Sandoval, PhD
  Question and Discussion Period

9:00 a.m.-10:00 a.m.

- Debate — Drawing the Line between Primary and Secondary Prevention — Necessary or Too Simplistic?
  Atherothrombotic Complications Necessary
  Christie M. Ballantyne, MD
  Too Simplistic
  Roger Scott Blumenthal, MD
  Heart Failure Complications Necessary
  Milton Packer, MD
  Too Simplistic
  Javed Butler, MD, MPH, MBA
  Question and Discussion Period

10:15 a.m.-12:15 p.m.

- Results of the eValuation of ERTugliflozin Efficacy and Safety CardioVascular Outcomes Trial (VERTIS-CV)
  Introduction, Study Rationale, and Design
  Richard E. Pratley, MD
  Baseline Characteristics and Metabolic Results
  Samuel Dagogo-Jack, MD, DSc
  Cardiovascular and Renal Outcomes
  Christopher Cannon, MD
  Safety Results and Updated Cardiovascular Meta-analysis
  Darren K. McGuire, MD, MHSc
  Overall Conclusions
  David Cherney, MD, PhD
  Independent Commentary
  Mark E. Cooper, MBBS, PhD